

HHV

National Strategic Plan **A Roadmap to End the Epidemic**

for the United States | **2021–2025**



VISION

The United States will be a place where new HIV infections are prevented, every person knows their status, and every person with HIV has high-quality care and treatment and lives free from stigma and discrimination.

This vision includes all people, regardless of age, sex, gender identity, sexual orientation, race, ethnicity, religion, disability, geographic location, or socioeconomic circumstance.

Acknowledgments: The HIV National Strategic Plan (HIV Plan) was developed through an inclusive and cooperative process that included input and feedback from stakeholders across public health, health care, research, and related fields. Partners throughout the federal government, as well as input from hundreds of nonfederal stakeholders including state, tribal, territorial, and local governments, researchers, health plans and providers, community groups, and national and local organizations that work in HIV and related fields, have helped shape the goals, objectives, and strategies in this Plan. The Office of the Assistant Secretary for Health (OASH) and its Office of Infectious Disease and HIV/AIDS Policy (OIDP) of the U.S. Department of Health and Human Services (HHS) sincerely thank all those who contributed to making this HIV Plan a reality.

Language used in the HIV Plan: The HIV Plan values the lived experiences and choices of all people, regardless of age, sex, gender identity, sexual orientation, race, ethnicity, religion, disability, geographic location, or socioeconomic circumstance. To reflect this vision, a concerted effort was made to use inclusive and person-first language throughout the HIV Plan. Evidence-based, contemporary terminology is also used to convey respect and empowerment and to reduce stigma faced by communities and populations disproportionately impacted by HIV. Despite these efforts, specific terminology or language may be unintentionally offensive or stigmatizing to some individuals or populations. This approach is intended to reflect the HIV Plan’s vision for a collective, inclusive, and respectful national response.

Additional information regarding the HIV Plan and associated activities may be accessed at <https://www.hiv.gov/>

Suggested citation: U.S. Department of Health and Human Services. 2021. *HIV National Strategic Plan for the United States: A Roadmap to End the Epidemic 2021–2025*. Washington, DC.

The HIV Plan is not a budget document and does not imply approval for any specific action under Executive Order 12866 or the Paperwork Reduction Act. The Strategy will inform the Federal budget and regulatory development processes within the context of the goals articulated in the President’s Budget. All activities included in the Strategy are subject to budgetary constraints and other approvals, including the weighing of priorities and available resources by the Administration in formulating its annual budget and by Congress in legislating appropriations.

TABLE OF CONTENTS

Executive Summary	1
I. Introduction	6
A. HIV Epidemic: Progress to Date.....	6
B. HIV in the United States Today.....	7
C. HIV National Strategic Plan: Roadmap to End the Epidemic 2021–2025.....	16
D. Priority Populations.....	18
E. Key Focus Areas.....	19
F. Development of the HIV National Strategic Plan.....	20
II. Goals and Related Objectives, Strategies, and Indicators of Progress	22
Goal 1: Prevent New HIV Infections.....	22
Goal 2: Improve HIV-Related Health Outcomes of People with HIV.....	31
Goal 3: Reduce HIV-Related Disparities and Health Inequities.....	37
Goal 4: Achieve Integrated, Coordinated Efforts That Address the HIV Epidemic among All Partners and Stakeholders.....	45
III. Implementation and Accountability	53
A. Federal Partners.....	53
B. Nonfederal Partners.....	53
Appendix A: Process/Methodology for Developing and Adopting the HIV Plan.....	54
Appendix B: Federal Steering Committee, Subcommittees, and Staff.....	63
Appendix C: Acronyms.....	68
Appendix D: References.....	70

Tables, Figures, and Boxes

Tables

Table 1.	Proportion of People with HIV by Race/Ethnicity Compared to Proportion of U.S. Population, 2018	9
Table 2.	HIV Transmissions in 2016.....	13
Table 3.	Definitions Included in the HIV Plan.....	21
Table A.1.	Composition of Joint Viral Hepatitis/HIV Federal Steering Committee	55
Table A.2.	Dominant Themes from Public Comments	57
Table A.3.	Priority Populations and Summary National-Level Data, Calendar Year 2018.....	58

Figures

Figure 1.	Annual HIV infections in the United States, 2014–2018	8
Figure 2.	HIV infections by race and transmission group, United States, 2014 vs. 2018	8
Figure 3.	HIV incidence by race/ethnicity, 2018.....	9
Figure 4.	57 jurisdictions prioritized in the <i>Ending the HIV Epidemic</i> initiative	10
Figure 5.	HIV prevention and treatment toolkits	11
Figure 6.	Prevalence-based HIV care continuum, 2018	13
Figure 7.	Status neutral approach to HIV	28
Figure 8 .	The HIV care continuum	31
Figure 9.	State criminal HIV exposure laws, as of 2020.....	42
Figure A.1.	Respondent type for all public comments with available affiliation	56
Figure A.2.	New HIV diagnoses in the United States and dependent areas for the most-affected subpopulations, 2018.....	60
Figure A.3.	Disparities along the HIV care continuum among Black gay, bisexual, and other men who have sex with men, 2018	61
Figure A.4.	Disparities along the HIV care continuum among youth, aged 13–24, 2018.....	61

Tables, Figures, and Boxes

Boxes

- Box 1. HIV National Strategic Plan and *Ending the HIV Epidemic: A Plan for America* 17
- Box 2. Missed Opportunities for HIV Diagnosis 24
- Box 3. Opportunities for Enhanced HIV Prevention Services in STD Specialty Clinics 25
- Box 4. HIV Testing Recommendations..... 27
- Box 5. Status Neutral Approach to HIV 28
- Box 6. Pharmacists’ Roles in HIV Prevention and Care 30
- Box 7. State HIV Criminalization Laws..... 41
- Box 8. Addressing HIV Prevention and Care Across the Lifespan 44

EXECUTIVE SUMMARY

Building on lessons learned and progress made in the past 40 years, the United States now has the opportunity to end the HIV epidemic. This opportunity has been made possible by tireless advocacy, determined research, and dedicated delivery of diagnostic, prevention, care, treatment, and supportive services.

The National HIV/AIDS Strategy, first released in 2010 and updated in 2015, changed the way Americans talk about HIV and the ways stakeholders prioritize and coordinate resources and deliver prevention and care services that support people with or at risk for HIV. The nation's new HIV infections have declined from their peak in the mid-1980s, and people with HIV in care and treatment are living longer, healthier lives. However, not all groups have experienced decreases in HIV infections or improvements in HIV-related health outcomes. In 2018, the estimated number of new HIV infections was 36,400. A robust prevention toolbox that includes pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP), and syringe services programs (SSPs) has lowered a person's risk of acquiring HIV. Research in recent years has proven that people with HIV who take antiretroviral therapy achieve and maintain an undetectable viral load not only protect their health but also have effectively no risk of transmitting HIV through sex.

This stability in the annual number of new infections, though, has further illuminated opportunities for focused efforts. According to the most recent available data, just over one-third (39%) of the U.S. population have ever been tested for HIV¹ and an estimated 161,800 (14%) people with HIV are unaware of their status.² Only 56% of people with HIV were virally suppressed in 2018.⁷ Approximately 80% of new HIV infections are due to people who do not know they have HIV or are not receiving regular care,⁴ and only 18% of the approximately 1.2 million people indicated for PrEP are receiving it.^{3,5}

This HIV National Strategic Plan (HIV Plan), the nation's third consecutive national HIV strategy, sets forth bold targets for ending the HIV epidemic in the United States by 2030, including a 75% reduction in new HIV infections by 2025 and a 90% reduction by 2030. For stakeholders across the nation, the HIV Plan articulates goals, objectives, and strategies to prevent new infections, treat people with HIV to improve health outcomes, reduce HIV-related disparities, and better integrate and coordinate the efforts of all partners to achieve the bold targets for ending the HIV epidemic in the United States. The HIV Plan also establishes indicators to measure progress, with quantitative targets for each indicator, and designates priority populations and key areas of focus.

The HIV Plan and the [Ending the HIV Epidemic: A Plan for America](#) (EHE) initiative are closely aligned and complementary, with EHE serving as a leading component of the work by the U.S. Department of Health and Human Services (HHS), in collaboration with local, state, federal, and community partners, to achieve the common goal. The EHE initiative is beginning in the jurisdictions now hardest hit by the epidemic. The HIV Plan covers the entire country, has a broader focus across federal departments and agencies beyond HHS and all sectors of society, and addresses the integration of several key components that are vital to our collective work, including stigma, discrimination, and social determinants of health.

VISION

The United States will be a place where new HIV infections are prevented, every person knows their status, and every person with HIV has high-quality care and treatment and lives free from stigma and discrimination.

This vision includes all people, regardless of age, sex, gender identity, sexual orientation, race, ethnicity, religion, disability, geographic location, or socioeconomic circumstance.

This vision is accompanied by four high-level goals, which frame the HIV Plan's more specific objectives. Strategies are articulated for everyone—federal and nonfederal stakeholders alike—to participate in working to achieve the goals through integrated individual-, community-, and structural-level responses. The order of goals, objectives, and strategies does not indicate any prioritization, and many are intertwined. The four goals and associated objectives are as follows:



Goal 1: Prevent New HIV Infections

- 1.1 Increase awareness of HIV
- 1.2 Increase knowledge of HIV status
- 1.3 Expand and improve implementation of effective prevention interventions, including treatment as prevention, PrEP, PEP, and SSPs, and develop new options
- 1.4 Increase the capacity of health care delivery systems, public health, and the health workforce to prevent and diagnose HIV



Goal 2: Improve HIV-Related Health Outcomes of People with HIV

- 2.1 Link people to care immediately after diagnosis and provide low-barrier access to HIV treatment
- 2.2 Identify, engage, or reengage people with HIV who are not in care or not virally suppressed
- 2.3 Increase retention in care and adherence to HIV treatment to achieve and maintain long-term viral suppression
- 2.4 Increase the capacity of health care delivery systems, public health, and the health workforce to serve people with HIV



Goal 3: Reduce HIV-Related Disparities and Health Inequities

- 3.1 Reduce HIV-related stigma and discrimination
- 3.2 Reduce disparities in new HIV infections, in knowledge of status, and along the HIV care continuum
- 3.3 Engage, employ, and provide public leadership opportunities at all levels for people with or at risk for HIV
- 3.4 Address social determinants of health and co-occurring conditions that exacerbate HIV-related disparities



Goal 4: Achieve Integrated, Coordinated Efforts That Address the HIV Epidemic among All Partners and Stakeholders

- 4.1 Integrate programs to address the syndemic of HIV, sexually transmitted infections (STIs), viral hepatitis, and substance use and mental health disorders
- 4.2 Increase coordination of HIV programs across all levels of government (federal, state, tribal, local, and territorial) and with faith-based and community-based organizations, the private sector, academic partners, and the community
- 4.3 Enhance the quality, accessibility, sharing, and use of data, including HIV prevention and care continuum and social determinants of health data
- 4.4 Identify, evaluate, and scale up best practices including through translational, implementation, and communication science research
- 4.5 Improve mechanisms to measure, monitor, evaluate, report, and disseminate progress toward achieving organizational, local, and national goals

Priority Populations

To focus efforts and resources for the greatest impact, the Steering Committee responsible for developing the HIV Plan reviewed national-level HIV surveillance data to identify populations disproportionately affected by HIV. Based on this analysis, the HIV Plan prioritizes efforts to reduce disparities and improve HIV outcomes among

- gay, bisexual, and other men who have sex with men, in particular Black,* Latino,* and American Indian/Alaska Native men;
- Black women;
- transgender women;
- youth aged 13–24 years; and
- people who inject drugs.

Key Areas of Focus

As with the previous iteration of the NHAS, this HIV Plan identifies key focus areas with the greatest potential to strengthen the national HIV response:

- Diagnose HIV as early as possible and promptly link people to care and treatment;
- Support all people with HIV to achieve and maintain viral suppression and improve health-related quality of life as they age with HIV;
- Scale-up PrEP awareness and access efforts for people for whom it is indicated and desired, particularly from Black and Latino communities, and support medication adherence and continued use;
- Address stigma, discrimination, and other social and structural determinants of health that inhibit HIV prevention, testing, and care; and
- Support the development and implementation of innovative approaches to mitigate the impact of viral hepatitis and STIs, especially syphilis, gonorrhea, chlamydia, and the connection of past and present trauma on the health outcomes for communities disproportionately affected by infectious diseases.

* For this HIV Plan, Black is defined as African American or Black and Latino is defined as Latino or Hispanic.

Indicators of Progress

Working together to pursue these objectives, the nation can achieve the following targets by 2025:

CORE INDICATORS

Indicator 1	Increase knowledge of status to 95% from a 2017 baseline of 85.8%
Indicator 2	Reduce new HIV infections by 75% from a 2017 baseline of 37,000
Indicator 3	Reduce new HIV diagnoses by 75% from a 2017 baseline of 38,351
Indicator 4	Increase PrEP coverage to 50% from a 2017 baseline of 12.6%
Indicator 5	Increase linkage to care within 1 month of diagnosis to 95% from a 2017 baseline of 77.8%
Indicator 6	Increase viral suppression among people with diagnosed HIV to 95% from a 2017 baseline of 63.1%
Indicator 7	Decrease stigma among people with diagnosed HIV by 50% from a 2018 baseline median score of 31.2 on a 10-item questionnaire
Indicator 8	Reduce homelessness among people with diagnosed HIV by 50% from a 2017 baseline of 9.1%

DISPARITIES INDICATORS

To monitor our progress in addressing HIV disparities, the viral suppression indicator is stratified by the priority populations:

Indicator 6a	Increase viral suppression among gay, bisexual, and other men who have sex with men (MSM) diagnosed with HIV to 95% from a 2017 baseline of 66.1%
Indicator 6b	Increase viral suppression among Black MSM diagnosed with HIV to 95% from a 2017 baseline of 58.4%
Indicator 6c	Increase viral suppression among Latino MSM diagnosed with HIV to 95% from a 2017 baseline of 64.9%
Indicator 6d	Increase viral suppression among American Indian/Alaska Native MSM diagnosed with HIV to 95% from a 2017 baseline of 67.3%
Indicator 6e	Increase viral suppression among Black women diagnosed with HIV to 95% from a 2017 baseline of 59.3%
Indicator 6f	Increase viral suppression among transgender women in HIV medical care to 95% from a 2017 baseline of 80.5%
Indicator 6g	Increase viral suppression among people who inject drugs diagnosed with HIV to 95% from a 2017 baseline of 54.9%
Indicator 6h	Increase viral suppression among youth aged 13–24 years diagnosed with HIV to 95% from a 2017 baseline of 57.1%

The vision, goals, objectives and other components of the HIV Plan were developed and approved by a dedicated Steering Committee, composed of subject matter experts from across the federal government, with input from numerous and varied stakeholders in the field. The HIV Plan is designed to be accessible to and useful for a broad audience, including people working in public health, health care, government, community-based organizations, research, and academia. It serves as a roadmap for stakeholders from all sectors of society to guide development of policies, services, programs, initiatives, and other actions to achieve the nation's vision of ending the HIV epidemic by 2030. While not every objective or strategy will speak to or be actionable by all readers, the intent is that individuals and organizations from all sectors of society can find opportunities where they can support necessary scale-up, expansion, and refinement efforts. Entities vital to ending the HIV epidemic in this country are located in rural or low to moderate HIV prevalence jurisdictions as well as higher prevalence ones and include community-based, faith-focused, and advocacy organizations; governmental public health; mental health and substance abuse treatment services; the criminal justice system; and providers of housing, food and nutrition, education, and employment services.

The HIV Plan focuses on four areas that will have the greatest impact on the health of the nation: preventing new HIV transmissions; improving health outcomes of people with HIV; reducing HIV-related disparities and health inequities; and better integrating and coordinating efforts that address the HIV epidemic among all partners and stakeholders. Because certain demographic groups and areas are disproportionately impacted by HIV, the HIV Plan also identifies priority populations and discusses the disproportionate impact of HIV in some geographic regions so that federal agencies and other stakeholders can focus their resources to achieve the greatest impact. The priority populations were identified based on national-level data. Stakeholders are encouraged to review their own data for the populations they serve to help focus their efforts.

Interwoven throughout the HIV Plan are approaches to address the individual, community, and structural factors and inequities that contribute to the spread of HIV, such as stigma and social determinants of health. The HIV Plan highlights opportunities to integrate HIV prevention, care, and treatment into STI, viral hepatitis, substance use disorders, and other public health efforts by leveraging capacity and infrastructure across the domains and breaking down operational and funding silos. A recurring theme is the need to bring to scale innovative solutions and approaches to address the ongoing and emerging challenges to HIV prevention, care, and treatment, including expanding the types of community and clinical sites that address HIV to help reach and engage people in need of services; supporting retention in HIV prevention and care services; continuing research into development of better prevention tools, therapeutics, and vaccines; and understanding how to make best use of these tools in real-world settings. The Plan is designed to facilitate a whole-of-society national response to the HIV epidemic in the United States that accelerates efforts to end the HIV epidemic in the United States by 2030 while reducing HIV-associated morbidity and mortality.

The HIV Plan includes indicators for measuring progress and quantitative targets for each indicator. There are eight core indicators, one of which is stratified to measure progress in addressing HIV disparities in the priority populations (i.e., disparities indicators). To ensure implementation and accountability, a Federal Implementation Plan that documents the specific actions that federal partners will take to achieve the HIV Plan's goals and objectives will be released subsequent to the HIV Plan. Progress toward meeting the HIV Plan's goals will be monitored and reported annually.

I. INTRODUCTION

A. HIV Epidemic: Progress to Date

After nearly 40 years of tireless advocacy, determined research, and dedicated delivery of diagnostic, prevention, care, treatment, and supportive services, the United States now has the opportunity to end the HIV epidemic. Since it was first discovered in 1981, HIV has affected the lives of millions of people across the nation. Today, through the ongoing commitment of stakeholders from many sectors, as well as landmark biomedical and scientific research advances, the nation has many effective HIV diagnostics, prevention strategies, and improved care and treatment models. New laboratory and epidemiological approaches enable us to identify where HIV is spreading most rapidly and to respond swiftly to stop the further spread of new HIV transmissions.

Over the past decade, the HIV response in the United States has been guided by the National HIV/AIDS Strategy (NHAS or Strategy), first released in 2010 and updated in 2015.[†] The Strategy has changed the way that Americans talk about HIV, prioritize and coordinate resources, and deliver prevention and care services along with other clinical and nonclinical services that support people with or at risk for HIV. It has also led to increased collaboration among federal agencies; people with or at risk for HIV; state, local, and tribal governments; health care providers; researchers; faith communities; and many other community partners. Since the release of the NHAS, several important achievements have bolstered the nation's HIV response:

- **Population-level viral suppression increased.** After the NHAS was released, the Centers for Disease Control and Prevention (CDC) published its first national estimates of the share of all people with HIV who have achieved viral suppression, finding that only about one in four people with HIV (27.9%) in the United States were virally suppressed in 2010.⁶ By 2018, however, viral suppression rates in the United States had more than doubled to 56.0%.⁷ Although still too low, these rates represent real progress.
- **HIV diagnoses declined, especially in key groups.** HIV diagnosis rates were relatively stable for many years prior to the release of the NHAS. CDC data suggest that annual new diagnoses declined by 11.4% from 2010 (43,806) when the Strategy was released to 2018 (38,789).⁷ Large declines occurred in some groups, including women. Deaths declined by 7.5%, from 2010 (16,742) to 2018 (15,483).⁸
- **Outcome disparities within the Ryan White HIV/AIDS Program were reduced.** Nearly 9 in 10 clients of the Health Resources and Services Administration's Ryan White HIV/AIDS Program (RWHAP) were virally suppressed in 2019, and the program continues showing progress at reducing disparities across groups.⁹ From 2010 to 2019, the gap between male and female clients decreased from nearly 5 percentage points to <1 percentage point. In addition, the gap between male and transgender clients decreased from 9 percentage points to 5 percentage points. Similarly, the difference between viral suppression rates in Black clients and white clients was 13 percentage points in 2010 but 7 percentage points in 2019.^{9,10}
- **Policy changes ensure that federal money follows the epidemic.** Earlier in the epidemic, federal HIV resources to states and local governments were either allocated via a discretionary manner or via a formula that relied on cumulative AIDS cases, skewing resources toward early epicenters of the epidemic and not reflecting the current burden of HIV across the country. Prior to release of the Strategy, Congress changed the formulas used by the RWHAP to be based on living HIV/AIDS cases. The Strategy's call for federal money to follow the epidemic spurred further action. In fiscal year 2012, CDC changed the formula for its major HIV prevention program for state and local health departments to be based on living HIV/AIDS cases, and, in 2016, Congress modernized the law that authorized the Housing Opportunities for Persons With AIDS (HOPWA) program to be based on living HIV/AIDS cases.

[†] This iteration is called the HIV National Strategic Plan to recognize the changing epidemiology of the HIV epidemic in the United States, as well as to align with the nomenclature used for the Sexually Transmitted Infections National Strategic Plan and the Viral Hepatitis National Strategic Plan.

- **The advent of pre-exposure prophylaxis (PrEP) has increased options for HIV prevention.** The first randomized controlled trial of PrEP reported results in 2010, and the U.S. Food and Drug Administration (FDA) approved the first PrEP medication in 2012. Several federal actions embraced this new biomedical tool as an important part of comprehensive HIV prevention: for example, CDC issued interim and then final prescriber guidance; the expansion of PrEP access was a central component of the 2015 Update to the NHAS; and the *Ending the HIV Epidemic: A Plan for America* (EHE) initiative further sought to remove barriers to PrEP uptake, including the establishment of the Ready, Set, PrEP program. Although uptake remains too low and disparities are large, the adoption of new medical technologies often takes decades, and the goal is to expedite widespread adoption of PrEP for people who can benefit from it.
- **Health insurance coverage rates for people with HIV have increased to match the general population.** In 2018, just 1 in 10 (11%) nonelderly people with HIV were uninsured, a rate on par with that of the general population (10%).¹¹ An estimated 42% of the adult population living with HIV is covered by Medicaid as compared to the just 13% of the overall adult population.¹³⁵ Medicaid is the largest source of insurance coverage for people with HIV, covering a broad range of services from inpatient and outpatient care, prescription medications, and preventive services.
- **Strategic investments by the National Institutes of Health (NIH) in research advanced efforts toward new prevention tools, next-generation therapies, a vaccine, and a cure.** NIH discovery science has been newly complemented by a suite of NIH implementation science projects designed to meet EHE initiative goals through improved use of proven HIV strategies.
- **States, cities, and local communities developed their own HIV strategies,** aligned with the NHAS and resulting in increased coordination across all sectors, including government agencies, nongovernmental organizations, and the private sector, to respond to the HIV epidemic, with new partnerships forged.
- **The *Ending the HIV Epidemic* initiative was launched in 2019 as a bold plan that aims to end the HIV epidemic in the United States by 2030.** EHE is the operational plan developed by agencies across the U.S. Department of Health and Human Services (HHS) to pursue that goal. The Plan leverages critical scientific advances in HIV prevention, diagnosis, treatment, and outbreak response by coordinating the highly successful programs, resources, and infrastructure of many HHS agencies and offices. In its first phase, the initiative is focused on areas where data show the highest numbers of new HIV infections, providing 57 geographic focus areas with a rapid infusion of additional resources, expertise, and technology to develop and implement locally tailored EHE plans.

B. HIV in the United States Today

HIV persists as a serious public health challenge in the United States. An estimated 1.2 million people in the United States had HIV at the end of 2018, the most recent year for which this information is available.² National HIV prevention and care efforts have taken us from a peak of 130,000 HIV infections annually in the mid-1980s¹² to approximately 36,400 in 2018.² Although HIV infection rates have decreased in the United States, new diagnoses continue in every U.S. state, with 37,968 new diagnoses occurring in 2018.

Our national progress has stalled in recent years, and not everyone is benefiting equally from advances in HIV prevention and treatment.

ANNUAL HIV INFECTIONS HAVE STABILIZED, UNDERSCORING THE NEED FOR IMMEDIATE ACTION

Progress in reducing new HIV infections has stalled in recent years, at about 38,000 new infections each year between 2014 and 2018.² (See Figure 1.) This overall stability masks important disparities. During this period, gay and bisexual men, Blacks, and Latinos bore the greatest burden of new HIV infections.² (See Figure 2.)




Figure 1. Annual HIV infections in the United States, 2014–2018




Figure 2. New HIV infections by race and transmission group, United States, 2014 vs. 2018²

HIV TREATMENT AND PREVENTION EFFORTS ARE NOT REACHING EVERYONE WHO NEEDS THEM

Although HIV remains a threat in every part of the United States, certain populations—and parts of the country—bear most of the burden, signaling where HIV prevention, care, and treatment efforts must be focused.

HIV by Population


Black and Latino communities are disproportionately affected by HIV compared to other racial/ethnic groups (see Table 1).

Table 1. Proportion of People with HIV by Race/Ethnicity Compared to Proportion of U.S. Population, 2018

Race/ethnicity	% of People with HIV, 2018 ²	% of U.S. Population, 2018 ¹³
Black	41%	13%
White	29%	60%
Latino	23%	18%
Asian	1.5%	6%
American Indian/Alaska Native	0.3%	1.3%
Native Hawaiians and Other Pacific Islanders	0.09%	0.2%

The disproportionate impact of HIV among Black and Latino communities is also evident in incidence (new infections). (See Figure 3.)

The latest incidence estimates indicate that effective **prevention and treatment are not adequately reaching people who could benefit most.**



* Includes American Indians/Alaska Natives, Asians, Native Hawaiians/Other Pacific Islanders, multiple races

Figure 3. HIV incidence by race/ethnicity, 2018²

In all regions of the United States, gay and bisexual men are by far the most affected group. They account for about 70% of new HIV infections each year, even though they make up only 2% of the population, with the highest burden among Black and Latino gay and bisexual men and young men.² In 2018, 26% of new HIV infections were among Black gay and bisexual men; 22% among Latino gay and bisexual men; and 46% among gay and bisexual men under the age of 35.

Among women, disparities persist. Black women are disproportionately affected compared to women of other races/ethnicities. Although annual HIV infections remained stable among Black women from 2014 to 2018, the rate of new HIV infections among Black women is 13 times that of white women and 4 times that of Latina women.²

Transgender women are also heavily affected. Available evidence suggests that in relation to their population size, transgender women are among the groups most affected by HIV in the United States: estimated HIV prevalence for transgender women is 14%¹⁴—a striking difference when compared to HIV prevalence estimates for adults in the U.S. overall (<0.5%).^{2,15}

In 2018, youth aged 13–24 years made up 21% of the 37,968 new HIV diagnoses in the United States and dependent areas. Youth with HIV are the least likely of any age group to be retained in care and have a suppressed viral load.¹⁶

In 2018, 7% of new HIV infections in the United States were among people who inject drugs (PWID). Long-term declining trends in HIV incidence among PWID have stalled, and new infections have begun to increase in some demographic groups. For example, in 2018 compared with 2014, the number of HIV infections increased 97% for white males with infection attributed to injection drug use. Localized outbreaks have contributed to these trends. This population is also at high risk for acquiring hepatitis C virus infection, and coinfection with HIV and hepatitis C is common (62–80%) among PWID with HIV.^{17,18,19}

HIV by Geography

Most of the nation's HIV diagnoses are concentrated in certain geographic areas, with the majority of diagnoses occurring in urban areas and southern states. In 2016 and 2017, more than half of new HIV diagnoses were concentrated in geographic hotspots across the United States: 48 counties plus Washington, DC, and San Juan, Puerto Rico.⁸ Seven states also have a substantial number of HIV diagnoses in rural areas.²⁰ These 57 jurisdictions are prioritized for the *Ending the HIV Epidemic: A Plan for America* initiative. Southern states account for 38% of the U.S. population but bear the highest burden of HIV infection with 53% of annual HIV infections, 46% of persons living with HIV, and 50% of people with undiagnosed infections.² (See Figure 4.)




Figure 4. 57 jurisdictions prioritized in Phase 1 of the *Ending the HIV Epidemic* initiative

This current landscape of HIV prevention, care, and treatment presents several opportunities and challenges that shape this 5-year plan.

OPPORTUNITIES

There are more tools than ever before to end the HIV epidemic in the United States. People who initiate antiretroviral therapy (ART) soon after diagnosis and remain adherent can live long, healthy lives.²¹ In addition, people with HIV who take ART and achieve and maintain an undetectable viral load have effectively no risk of transmitting HIV through sex.^{22,23,24,25} Thanks to a robust toolbox that includes syringe services programs (SSPs), PrEP, and post-exposure prophylaxis (PEP), and treatment as prevention, an individual's risk of acquiring HIV is significantly lower (see Figure 5).




Figure 5. HIV prevention and treatment toolkits. Source: Eisinger et al.²⁶ Published by Oxford University Press for the Infectious Diseases Society of America 2019. This work is written by (a) U.S. Government employee(s) and is in the public domain in the U.S. Image modified with permission of authors.

To realize the full potential of these tools, several opportunities exist to expand the capacity of existing public health infrastructure, health care systems, and the workforce. Engaging people with and affected by HIV in community planning for and delivery of HIV prevention and care services is essential to realizing the full potential of these tools. Further, expanding partnerships and training among traditional settings and stakeholders as well as identifying and working with nontraditional partners that are likely to engage people with or at risk for HIV will better leverage the capacities of more stakeholders to facilitate access to HIV diagnostics, prevention, care, treatment, and supportive services. Key to the success of such efforts will be engaging and collaborating with partners that may not regularly provide HIV services but could reach and engage people with or at risk for HIV who have not been effectively reached by existing efforts.

Importantly, the availability and use of data from a variety of sources, along with national, state, and local (and even clinic-level) indicators and targets, can help guide decision-making, service planning, and resource allocation.

Along with better use of data, ensuring that community-driven planning and decision-making include more diverse voices, expertise, and experiences can enhance how programs and services are tailored, implemented, and assessed to reach the populations that need them.

During the lifespan of this HIV Plan, long-acting therapeutics and other simplified HIV drug regimens may become available. The overall value, potential impact, and cost-effectiveness of each new HIV testing, prevention, care, or treatment intervention must be demonstrated. Policy and program development should occur in parallel with the review and approval process for any new prevention or treatment options, such as long-acting injectables or implantables. These efforts should incorporate formative research and conversations with all relevant stakeholders especially patients, providers, and payers to identify challenges and opportunities to prevent gaps between the approval, implementation, and uptake stages. In this way, new treatment or prevention products could better address the needs of people for whom existing interventions have not been effective or who have struggled with adherence.

Ongoing HIV research will facilitate progress toward HIV prevention, treatment, addressing of co-occurring health conditions, and better understanding and addressing of HIV disparities and inequities while advancing novel approaches toward long-term HIV remission and the ultimate goal of an HIV cure.

These opportunities and developments, among others, will continue to transform and help guide the nation's approach to HIV through 2025.

CHALLENGES

Although the United States is making significant progress in improving HIV outcomes, significant challenges remain. Gaps in the HIV care continuum (see Figure 6) are driving HIV transmission. By ensuring that everyone with HIV is aware of their status, receives the treatment they need, and achieves and maintains viral suppression—key steps in the HIV care continuum—we can preserve the health of people with HIV, improve the quality of their lives, and drive down new HIV infections.

Biomedical HIV Prevention Tools

PrEP is medicine that people at risk for HIV take to prevent getting HIV from sex or injection drug use.

PEP is HIV medicine used in emergency cases for people who have possibly been exposed to HIV. People must start taking the pill within 72 hours of exposure.

Treatment as Prevention is a highly effective prevention method in which people with HIV take HIV medication daily as prescribed and get and keep an undetectable viral load. As a result, they have effectively no risk of sexually transmitting HIV to their HIV-negative partners. This is often referred to as U=U or “undetectable = untransmittable.”




Figure 6. Prevalence-based HIV care continuum, United States, 2018

However, the most recent data available (2018) show the following:

- Less than one-half (39%) of the U.S. population has ever been tested for HIV.¹
- Of people with HIV, an estimated 161,800 (14%) were unaware of their status,² meaning they are not receiving the care they need to stay healthy and prevent transmission to others. The proportion unaware is especially high in the South, likely contributing to the high burden of HIV in the region.
- One in three people with HIV (35%) are not receiving needed HIV care.
- Only 56% of people with HIV were virally suppressed, meaning that 44% are not receiving the benefits of HIV treatment.³

Those gaps in the care continuum are challenges to be addressed because, according to a CDC transmission model based on 2016 data, approximately 80% of new HIV infections are due to people who do not know they have HIV or are not receiving regular care (see Table 2).⁴

Table 2. HIV Transmissions in the United States, 2016

% of People with HIV	Status of Care	Accounted for X% of New Transmissions ^a
15%	Didn't know they had HIV	38%
23%	Knew they had HIV but weren't in care	43%
11%	In care but not virally suppressed	20%
51%	Taking HIV medicine and virally suppressed	0%

^a Total does not equal 100% because of rounding.

Note: CDC analysis shows that the vast majority (about 80%) of new HIV infections in the United States in 2016 were transmitted from the nearly 40% of people with HIV who either did not know they had HIV, or who received a diagnosis but were not receiving HIV care.²⁷

In addition to these gaps in HIV diagnoses, care, and treatment, there are HIV prevention challenges. Only 18% of the approximately 1.2 million people indicated for PrEP are receiving it; therefore, about 4 in 5 people who could benefit from PrEP are not receiving it. Further, significant disparities in PrEP coverage persist based on race/ethnicity, gender, and age.^{3,5} Among those who initiate PrEP, adherence and long-term maintenance can be a challenge.^{28,29}

Although anyone can acquire HIV, the epidemic disproportionately affects specific populations, communities, and geographic areas across the United States. These disparities exist among gay, bisexual, and other men who have sex with men (MSM), especially Black, Latino,[‡] and American Indian/Alaska Native men. They also exist among Black women, transgender women, youth (particularly gay and bisexual young men and transgender youth), and people who inject drugs. These gaps remain particularly troublesome not only among disproportionately affected populations, but also in some rural areas and the South. In 2018, it was estimated that more than one-half of new HIV infections occurred in the South.²

Inequities in the social determinants of health are significant contributors to health disparities and highlight the need to focus not only on HIV prevention and care efforts, but also on how programs, practices, and policies affect communities of color and other populations that experience HIV disparities.

Racial and ethnic minority groups are more likely to be uninsured compared to non-Hispanic whites, limiting their access to health care. Barriers to health care access include lack of transportation and childcare, inability to take time off work, experiences with housing instability or homelessness, communication and language barriers, racism, discrimination, and lack of trust in health care providers.

Sexual and gender minority populations also face health disparities.^{30,31,32,33,34} Barriers to health care include stigma, discrimination, medical mistrust, safety, and lack of access to affirming mental health care.³⁵ Sexual and gender minorities face greater health challenges than heterosexuals due in part to inequities such as stigma and discrimination.³⁶ Sexual and gender minority populations have lower levels of health insurance and access to regular health care compared to heterosexuals.^{37,38}

Another threat to achieving national HIV prevention and care goals is the increase in drug use resulting from both the nation's opioid and resurgent use of methamphetamine and other stimulants among gay men and others who face higher risk for HIV. Increases in drug use are linked to rising rates, and even outbreaks, of several infectious diseases including hepatitis A, hepatitis B, hepatitis C, and HIV,³⁹ which threaten the progress to date to reduce HIV transmission, particularly among people who inject drugs. Recognizing this threat, in 2016, CDC identified 220 counties in 26 states that are vulnerable to HIV and viral hepatitis as a result of the opioid epidemic.⁴⁰ In a recent study of HIV-negative sexual and gender minorities who have sex with men that included a substantial proportion who used crystal meth, the highly addictive drug emerged as the dominant risk factor associated with HIV seroconversion, with persistent methamphetamine users accounting for one-third of all observed HIV seroconversions in the study.⁴¹ Using drugs or alcohol may lead to sexual behaviors (e.g., having sex without a condom, having multiple partners) that increase the risk of getting or transmitting HIV. For people with HIV, substance use can hasten disease progression and negatively affect care retention and treatment adherence.⁴²

Rising rates of sexually transmitted infections (STIs) also threaten efforts to reduce new HIV infections.^{43,44} STIs are associated with a higher risk of transmitting or acquiring HIV.¹³⁶ A recent modeling analysis estimated that 10% of HIV infections in gay and bisexual men were attributable to untreated gonorrhea and chlamydia.⁴⁵ Siloed program delivery leads to missed opportunities to screen, link, and provide navigation, care management, and treatment for people with HIV, STIs, viral hepatitis, and substance use and/or mental health disorders.

[‡] For this HIV Plan, Black is defined as African American or Black; and Latino is defined as Latino or Hispanic.

HIV, STIs, VIRAL HEPATITIS, AND SUBSTANCE USE DISORDERS—A HOLISTIC APPROACH TO THE SYNDEMIC

The interacting, synergistic effect of linked health conditions such as HIV, viral hepatitis, STIs, and substance use and mental health disorders that contribute to excess burden of disease in a population is known as a syndemic. Addressing a syndemic in populations, communities, and people can be challenging because it requires integrated and simultaneous efforts across respective prevention, screening, diagnosis, and treatment programming as well as rapid implementation of new scientific advances. These integrated efforts must go beyond the disease-specific responses to include identifying and addressing root causes that are fueling the syndemic, with greater disease risk and poorer health outcomes often rooted in the social determinants of health, requiring responses to issues of stable housing, employment, and safety. A holistic approach to addressing the syndemic can only be effective if we continue to explore the connection between trauma and infectious diseases. Past and present trauma contribute to the excess burden of disease in many communities at risk for or diagnosed with HIV, STIs, viral hepatitis, and substance use and mental health disorders. This burden challenges collective efforts to provide prevention and care services because trauma-informed service models are not fully developed, and ready access to substance use treatment and mental health care may be lacking. However, the opportunity exists to bolster coordination, capacity, and delivery of services to populations at risk for these linked conditions. To help drive a coordinated response to the syndemic, the HIV Plan was developed concurrently with the next iteration of the Viral Hepatitis National Strategic Plan (Viral Hepatitis Plan) and the inaugural Sexually Transmitted Infections National Strategic Plan (STI Plan). The HIV National Strategic Plan recognizes that trauma is part of the syndemic and that better understanding of the connection between past and present trauma is critical to improving health outcomes in certain communities.

These interrelated health conditions present potential challenges to achieving national HIV goals. Yet, recognizing each of them as well as the syndemic presents an opportunity to conduct relevant research and analyses, develop evidence-based interventions and policy options, and allocate resources to respond efficiently and effectively.

COVID-19 and the Syndemic

This Plan is being released during an unprecedented pandemic. In early 2020, SARS-CoV-2, the coronavirus that causes COVID-19 disease, spread rapidly across the globe and the United States, infecting millions, claiming the lives of more than 1.5 million people, and causing great uncertainty, including for people with and at risk for HIV, STIs, and viral hepatitis.

The pandemic has exacerbated existing challenges in the nation's public health and health care systems, further exposing decades, if not centuries, of health inequities driven by the social determinants of health. Many clinical and public health services have been curtailed due to the pandemic, with many staff understandably redeployed to address the public health emergency. Many of the populations and communities disproportionately affected by HIV, STIs, and viral hepatitis are particularly vulnerable to the service disruptions and the economic consequences of the pandemic, including unemployment, housing and food insecurity, and obstacles to practicing safe social distancing. The economic impact of the pandemic may have long-lasting impacts on health services availability, because of budget constraints and possible permanent closures or reductions in hours of clinics and practices. It may also exacerbate the socioeconomic conditions that people face, exacerbating some social determinants of health affecting disease risks and health outcomes. Implementation of the HIV Plan should take into account these emergent and potential long-term effects.

A **syndemic** is a set of linked health problems that interact synergistically and contribute to excess burden of disease in a population.

A syndemic occurs when health-related problems cluster by person, place or time.

Social determinants of health and stigma also play a significant role in this syndemic.

As the nation responds to the pandemic, while working to maintain HIV, STI, and viral hepatitis prevention, screening, and care, innovative approaches have evolved to continue providing services, such as meeting with clients via telemedicine, distributing self-testing kits, increasing the use of expedited partner therapy to ensure timely STI treatment, offering multi-month medication refills, and partnering with pharmacies and retail health clinics to ensure continuity of care. Some of these adaptations may prove to be sustainable and effective in achieving our national goals. Stakeholders should engage in a process to assess which of these innovations and flexibilities should be made a permanent part of HIV prevention and care programs and services. This process should address areas of the nation, where adopting these new approaches was challenging or not possible due to capacity and infrastructure issues, most notably in rural and remote areas.

Our understanding of COVID-19 will continue to evolve as effective therapeutics and vaccines are developed and implemented. The ways in which the COVID-19 pandemic will continue to influence our responses to STI, HIV, and viral hepatitis remain unknown. However, stakeholders' commitment to addressing the syndemic remains firm. The nation's evolving response will require continued engagement with affected communities as well as innovation and identification of opportunities to integrate and leverage resources and lessons that advance efforts to address infectious diseases that threaten public health.

C. HIV National Strategic Plan: Roadmap to End the HIV Epidemic 2021–2025

This HIV Plan, updated for 2021–2025, builds on the lessons learned and progress of previous iterations and seeks to leverage opportunities and address the challenges that remain. It provides a national roadmap for continuing the coordinated response to HIV and puts the country on the path to end the HIV epidemic in the United States by 2030. The HIV Plan is guided by this vision statement:

VISION

The United States will be a place where new HIV infections are prevented, every person knows their status, and every person with HIV has high-quality care and treatment and lives free from stigma and discrimination.

This vision includes all people, regardless of age, sex, gender identity, sexual orientation, race, ethnicity, religion, disability, geographic location, or socioeconomic circumstance.

This HIV Plan includes the following:

- Four goals to achieve this vision, specific objectives for each goal, and strategies for each objective. The goals, objectives, and strategies are updated to reflect lessons learned and the efforts necessary to end the HIV epidemic;
- Five key areas of focus with the highest expected impact on the national response to HIV;
- Priority populations, identified by national-level data as disproportionately affected by HIV, to help focus stakeholder efforts and resource allocation; and
- Eight core indicators and one disparities indicator stratified for each priority population with quantitative targets to track progress toward achieving national HIV goals.

The HIV Plan's objectives and strategies are intended to be implemented by a broad mix of stakeholders at all levels and across many sectors, both public and private. They also serve as a tool to foster a shared focus, enhance coordination of efforts across agencies and programs, and identify areas of synergy and new opportunities to sharpen collective efforts. The strategies are intended to be scalable by implementer type and size of population to be served.

The HIV Plan adopts bold targets for ending the HIV epidemic in the United States by 2030, calling for a 75% reduction in new HIV infections by 2025 and a 90% reduction by 2030. The HIV Plan's goals, objectives, and strategies focus on achieving national targets set for 2025, setting the stage to ultimately end the HIV epidemic by 2030. As such, the HIV Plan's vision, goals, objectives, strategies, indicators, and quantitative targets align with the *Ending the HIV Epidemic* initiative, which complements and will serve as one of many important implementation elements of the HIV Plan (see Box 1). The HIV Plan's indicators and quantitative targets also align with *Healthy People 2030*.

A Federal Implementation Plan describing specific actions that federal agencies across the government will undertake from 2021 to 2025 to achieve the HIV Plan's goals and objectives will be developed and released. The Federal Implementation Plan will also increase transparency and accountability and promote coordination and collaboration among the various departments and agencies. Progress toward meeting the HIV Plan's goals, including updates on federal commitments and highlights from nonfederal actions, will be reported regularly.



BOX 1

THE HIV NATIONAL STRATEGIC PLAN AND *ENDING THE HIV EPIDEMIC: A PLAN FOR AMERICA*

The HIV Plan and [Ending the HIV Epidemic: A Plan for America](#) (EHE) initiative are complementary, with EHE serving as a leading component of the work by the U.S. Department of Health and Human Services (HHS), in collaboration with federal, state, and local partners, to achieve the common goal. Phase I of EHE focuses on the geographic areas in the country with the highest HIV disease burden and will be expanded in Phases II and III. The HIV Plan specifically addresses integration of efforts related to the other components of the syndemic, stigma, discrimination, and social determinants of health; has a broader focus across the federal government, including agencies beyond HHS; and seeks to engage all sectors of society. The HIV Plan covers the entire country and encourages federal collaboration to support locally driven solutions to help reach the 5-year goals as outlined in this strategy.

In February 2019, the Administration's goal to end the HIV epidemic in the United States within 10 years, was announced. To achieve this goal, HHS launched EHE to leverage available data and tools. The initiative aims to reduce new HIV transmissions in the United States by 75% by 2025 and by 90% by 2030. EHE outlines four pillars to achieve this goal:

- Diagnose all people with HIV as early as possible.
- Treat people with HIV rapidly and effectively to reach sustained viral suppression.
- Prevent new HIV transmissions by using proven interventions, including preexposure prophylaxis (PrEP) and syringe services programs (SSPs).
- Respond quickly to potential HIV outbreaks to get prevention and treatment services to people who need them.



BOX 1, *continued*

THE HIV NATIONAL STRATEGIC PLAN AND ENDING THE HIV EPIDEMIC: A PLAN FOR AMERICA

More than one-half of new HIV diagnoses in 2016 and 2017 occurred in 48 counties, Washington, DC, and San Juan, Puerto Rico. In addition, seven states have a disproportionate occurrence of HIV in rural areas. From 2020 to 2025 (Phase I), EHE will focus on a rapid infusion of new resources, expertise, and technology into these jurisdictions. During Phase II, efforts will be even more widely disseminated across the nation to reduce new infections by 90% by 2030. During Phase III, ongoing care and treatment and intensive case management will be implemented to maintain the number of new infections at fewer than 3,000 per year.

Both the HIV Plan and EHE align to end the HIV epidemic in the United States by 2030. The HIV Plan is the entire nation's road map to a holistic approach to engaging a broad range of stakeholders across many sectors of society to help achieve national goals to end the HIV epidemic.

D. Priority Populations

Although HIV affects millions of Americans nationwide and from all social, economic, and racial and ethnic groups, and in all parts of the country, it disproportionately affects certain populations. The disproportionate prevalence of HIV in specific populations increases the risk for HIV transmission with each sexual or injection drug use encounter within those populations. In addition, a range of social, economic, and demographic factors—such as stigma, discrimination, socio-economic status, income, education, age, and geographic region—affect people's risk for HIV or their ability to access or remain engaged in prevention or care services.

To focus effort and resources for the greatest impact, the Steering Committee responsible for developing the HIV Plan and its Indicators Subcommittee (see Appendix B) reviewed national-level HIV surveillance data to identify populations disproportionately affected by HIV. They explored the following factors: (1) incidence of new HIV infections and trends; (2) prevalence of HIV; (3) HIV diagnoses; (4) outcomes along the HIV care continuum; and (5) potential impact of other major public health threats (e.g., opioid epidemic). Based upon this analysis, the HIV Plan prioritizes efforts to reduce disparities and improve HIV outcomes among the following:

- gay, bisexual, and other men who have sex with men, in particular Black, Latino, and American Indian/Alaska Native men;
- Black women;
- transgender women;
- youth aged 13–24 years; and
- people who inject drugs.

Focusing efforts on these five priority populations will reduce the HIV-related disparities they experience, which is essential if the nation is to succeed on the path toward ending the HIV epidemic by 2030. This focus should not diminish efforts to prevent, diagnose, and treat HIV, more generally, for all populations affected by HIV, who remain a critical concern throughout this Plan. For example, just over one-half of the people with diagnosed HIV in the United States today are over age 50. While this statistic is a marker of the success of modern HIV treatment, it signals the need to tailor services to support this population, which includes long-term survivors of HIV as well as those more recently diagnosed with HIV, to continue to remain engaged in care and virally

suppressed and to meet their evolving needs related to comorbidities often associated with aging. Similarly, people experiencing unstable housing or homelessness are known to have lower rates of viral suppression, thus requiring their own unique services to support engagement in care and viral suppression.

To drive action and measure progress toward reducing health inequities and disparities among the priority populations, the HIV Plan uses viral suppression, stratified by population, as an indicator. Viral suppression was selected as the disparities indicator because increasing and maintaining viral suppression among priority populations will improve health outcomes, reduce HIV-related death, and prevent new HIV transmissions. Monitoring progress on these disparities indicators also helps ensure that the nation is making progress with all populations, leaving no groups behind.

Local partners and stakeholders must use local data to identify the populations most affected in their communities and to understand outcomes for each along the continuum of HIV prevention and care. Each state, tribe, community, program, or clinic will make its own assessment of relevant priority populations so that programs and services can be tailored and focused accordingly. In some jurisdictions, local surveillance and program data may indicate that additional populations not mentioned here are experiencing persistent HIV disparities that require focus from local efforts.

In addition, some stakeholders may work with specific populations or communities in a limited area with data that vary somewhat from the national data. For example, on a federal level, agencies such as the Indian Health Service, CDC's Division of Adolescent and School Health, Department of Veterans Affairs, Federal Bureau of Prisons, and Administration for Community Living serve distinct populations with or at risk for HIV. Likewise, state, tribal, territorial, and local jurisdictions, as well as schools and other institutions, may serve distinct populations. For these and other stakeholders, efforts should be guided by an assessment of health disparities within their purview and/or jurisdiction to determine how best to focus available resources to achieve results with the greatest impact.

A more detailed discussion of determining priority populations is in Appendix A.

E. Key Focus Areas

As with the previous iteration of the NHAS, this HIV Plan identifies key focus areas with the greatest potential to strengthen the national HIV response:

- **Diagnose people with HIV as early as possible and promptly link them to care and treatment.** Early detection helps people enter care and treatment soon after acquiring HIV and prevents HIV transmission to others. Increased awareness about HIV and availability of low-barrier HIV testing for people for whom it is recommended and desired are ongoing needs. Programs that can diagnosis and prescribe immediate ART provide key opportunities to improve health outcomes for people with HIV.
- **Support all people with HIV to achieve and maintain viral suppression** and improve health-related quality of life as they age with HIV. Achieving and maintaining HIV viral suppression provides important health and prevention benefits for people with HIV and the nation as a whole. In order to increase the proportion of people with HIV who are durably virally suppressed, the nation must continue to make improvements across the HIV care continuum to ensure that as many people living and aging with HIV as possible can achieve each successive step. Also necessary is the provision of whole-person care that addresses noncommunicable comorbidities and co-infections, such as viral hepatitis and other STIs, that often impact the health of people with HIV, and other obstacles to remaining in care and treatment.
- **Scale-up PrEP awareness and access efforts for people for whom it is indicated and desired, particularly from Black and Latino communities, and support medication adherence and continued use.** An analysis showed a correlation between increased PrEP uptake and decreases in new HIV diagnoses in United States.⁴⁶ PrEP use is also associated with increased engagement in ongoing health care, reduced anxiety

related to HIV and other STIs, increased sexual pleasure, and reduced stigma toward people with HIV.⁴⁷ Given the strength of the scientific evidence and its potential to reduce new HIV infections, the HIV Plan continues to recognize the need to increase awareness, access, and adherence to PrEP as well as support people in addressing clinical or financial barriers to their continued use of PrEP. However, PrEP may not be the desired or appropriate HIV prevention option for all people, so continued promotion of the full array of highly effective HIV prevention options and research into new prevention tools remain important.

- **Address stigma, discrimination, and other social and structural determinants of health that inhibit HIV prevention, testing, and care.** Every person with or at risk for HIV should receive diagnostic, preventive, care, treatment, and supportive services that are non-stigmatizing, or non-discriminatory, competent, and responsive to their needs.
- **Support the development and implementation of innovative approaches to mitigate the impact of viral hepatitis and STIs and the connection of past and present trauma on the health outcomes for communities disproportionately affected by infectious diseases.** This focus area includes supporting additional implementation research efforts for both prevention and care and the creation of new partnerships as a part of an integrated approach to screening, prevention, and treatment of people and populations with high rates of concurrent infectious diseases.

F. Development of the HIV National Strategic Plan

A Steering Committee, representing 6 federal departments and 14 HHS agencies and offices, oversaw the development of the HIV Plan and, concurrently, the Viral Hepatitis Plan. The Steering Committee set the vision, goals, and priority populations for the nation; identified and discussed key challenges to be addressed in each updated strategy; and prioritized best practices. The HIV Plan was informed by input from a wide range of stakeholders gathered through 18 in-person and virtual listening sessions and two Requests for Information published in the *Federal Register*, which elicited hundreds of comments (see Appendix A).

Recognizing the importance of addressing the syndemic of HIV, STIs, viral hepatitis, and substance use and mental health disorders, the HIV Plan was developed concurrently and in alignment with the next iteration of the Viral Hepatitis Plan and the inaugural STI Plan. Together, these three plans aim to enhance coordination of the activities of federal agencies and diverse community stakeholders to reduce morbidity and mortality, stigma, discrimination, health inequities, and disparities; improve outcomes; and fortify a strengthened public health and health care infrastructure to support prevention, diagnosis, care, and treatment across these infectious diseases. To that end, federal activities to implement the three plans will be aligned and synergized where possible. The next iteration of the Vaccines National Strategic Plan will also align with elements of these three plans.

The HIV Plan sets forth four goals, objectives for each goal, and strategies for each objective (see Table 3 for definitions). These objectives and strategies are designed to guide federal partners and other stakeholders in achieving the HIV Plan's vision and goals. The objectives provide direction for the attainment of each goal. The strategies recommend approaches to achieve the objectives. Numerous objectives and strategies could fit under more than one goal. However, each one has been placed under the goal in which it most closely aligns.

A separate HIV Federal Implementation Plan will be developed and will detail federal partners' plans and activities to implement the goals, objectives, and strategies set forth in this document. During the development of that plan, the federal partners involved in this strategic plan will explore opportunities to engage other federal departments or agencies that could scale up HIV-related services or that administer programs or support delivery of services that can help address social determinants of health and reduce health disparities and, as such, could make vital contributions to national efforts to end the HIV epidemic.

Table 3. Definitions Included in the HIV Plan

HIV National Strategic Plan	Federal Implementation Plan
<p>Goals: Broad aspirations that enable a plan’s vision to be realized</p> <p>Objectives: Changes, outcomes, and impact a plan is trying to achieve</p> <p>Strategies: Choices about how best to accomplish objectives</p>	<p>Action Steps: Specific activities that will be performed to implement the strategies and achieve the goals of the plan</p> <p>Progress Reports: Reports on progress, successes, and challenges</p>

^a Adapted from the HHS Office of the Assistant Secretary for Planning and Evaluation.

II. GOALS AND RELATED OBJECTIVES, STRATEGIES, AND INDICATORS OF PROGRESS



Goal 1: Prevent New HIV Infections

THE OPPORTUNITY

The most effective ways to reduce new HIV infections are to ensure timely diagnosis and engagement in care and treatment for people with HIV so that they achieve and maintain viral suppression and therefore cannot transmit the virus; target prevention resources to the places with the largest disease burden and the populations at greatest risk; and ensure that the most effective prevention strategies are prioritized and widely implemented.

An ongoing emphasis on primary prevention remains important. As CDC observes, not having sex is a 100% effective way to prevent getting or transmitting HIV through sexual activity. Also, for those engaging in sexual activity, reducing the number of sexual partners, choosing sexual practices with less risk of transmission, getting tested and treated for STIs, using PrEP, and having open and honest communication with your partners about your HIV status and sexual history are reliable ways to avoid HIV. CDC also notes that correct and consistent use of condoms is highly effective in reducing HIV transmission.⁴⁸

Continued research into the best use of existing prevention tools as well as new options, including PrEP, microbicides, and vaccines, is also necessary.

Because of advances and innovations during the past decade, an array of HIV prevention options, for use in combination or on their own, are available to people with or at risk for HIV, including the following:

- **HIV treatment as prevention.** HIV treatment is now a key HIV prevention tool. Evidence has definitively shown that people with HIV who achieve and maintain an undetectable viral load by taking HIV medication as directed will not sexually transmit the virus to an HIV-negative partner. This finding has giving rise to the understanding of “treatment as prevention.” In these studies, no HIV infections occurred within mixed-status couples, even in the absence of condoms or PrEP, when the HIV-positive partner had a suppressed viral load (defined as having a viral load of less than 400 copies of HIV RNA per milliliter). Therefore, a grassroots movement has emerged to promote the value of HIV treatment as prevention through the “Undetectable = Untransmittable” campaign, also known as U=U.



GOAL 1: PREVENT NEW HIV INFECTIONS

Objectives

- 1.1 Increase awareness of HIV
- 1.2 Increase knowledge of HIV status
- 1.3 Expand and improve implementation of effective prevention interventions, including treatment as prevention, PrEP, PEP, and SSPs, and develop new options
- 1.4 Increase the capacity of health care delivery systems, public health, and the health workforce to prevent and diagnose HIV

- **HIV testing and linkage to care.** People who test positive for HIV can take steps to prevent others from being exposed to the virus.⁴⁹ However, nearly 40% of people with HIV are unaware of their status or are diagnosed but not receiving care. In 2016, people unaware or not receiving care accounted for nearly 80% of new HIV infections in the United States.⁴ This finding underscores the critical roles of testing, prompt linkage to HIV care and treatment, and ongoing support services in preventing new HIV transmissions.

People who take HIV medications daily as prescribed to achieve and maintain an undetectable viral load have **effectively no risk** of sexually transmitting HIV to HIV-negative partners.

- **PrEP.** Uptake of daily oral PrEP, which reduces the risk of getting HIV from sex by about 99% when taken daily, has climbed in recent years. After reviewing the available research on PrEP, in June 2019 the U.S. Preventive Services Task Force (USPSTF) issued a Grade A recommendation for providers to offer PrEP to people at high risk for HIV.⁵⁰ With this recommendation, beginning in January 2021, patients with private insurance plans subject to preventive service requirements or health coverage through Medicaid Expansion can receive first-dollar coverage (no cost-sharing) for their PrEP medication. In addition, in 2019 FDA approved a second drug for PrEP and a generic version of the original drug became available, increasing options for people who wish to use PrEP. EHE's nationwide [Ready, Set, PrEP program](#) is helping to increase access to PrEP by making the medications available at no cost to people who lack prescription drug coverage.
- **SSPs and other harm reduction services.** The sharing of needles and other drug paraphernalia increases the risk for HIV and other blood-borne infections such as viral hepatitis. SSPs are community-based prevention programs that provide a range of services, including linkage to substance use disorder treatment; access to sterile syringes and safe disposal of used syringes and other equipment; and vaccination, testing, and linkage to care and treatment for infectious diseases. Nearly 30 years of research shows that comprehensive SSPs are safe, effective, and cost-saving; do not increase illegal drug use or crime; and play an important role in reducing the transmission of HIV, viral hepatitis, and other infections.⁵¹ Appropriations language from Congress permits the use of funds from HHS, under certain circumstances, to support SSPs with the exception that funds may not be used to purchase needles or syringes. [Multi-agency guidance](#) was issued on this opportunity, and in 2020 CDC published a [technical package](#) on effective strategies and approaches for planning, design, and implementation of SSPs.
- **PEP, condoms, and other effective prevention interventions.** Other prevention methods have been shown to be effective. Post-exposure prophylaxis (PEP) is a short course of HIV medicines taken very soon after a possible exposure to HIV to prevent the virus from taking hold in the body. PEP should be used only in emergency situations and must be started within 72 hours after a recent possible exposure to HIV. Correct condom use remains one of the most effective methods to reduce the risk of HIV transmission during sexual activity. Further, reducing the number of sexual partners lowers the likelihood of having a partner who can transmit HIV, engaging in other safer sex practices that avoid exchanging body fluids decreases risk, getting treated for other STIs can reduce risk of transmitting or acquiring HIV, and practicing abstinence completely eliminates the chance of being exposed to HIV.

In addition, a range of HIV prevention or multipurpose prevention products are under development or regulatory review, which could result in even more HIV prevention tools becoming available within the 5-year span of this Plan.

CHALLENGES

To achieve the goal of reducing new infections the following challenges must be addressed:

- Many people in the United States still do not have the basic facts about HIV, including information on the latest prevention options and the effectiveness of HIV treatment.⁵²
- People at high risk for HIV are either not offered or do not receive HIV testing when visiting health care providers.⁵³ (See Box 2.)

- Sexually transmitted diseases (STDs) are surging in the United States, reaching an all-time high in 2018.[§] From 2014 to 2018, the rates of reported cases of primary and secondary syphilis, congenital syphilis, gonorrhea, and chlamydia rose 71%, 185%, 63%, and 19%, respectively.⁵⁴ The presence of STDs increases the risk of transmitting or acquiring HIV. Improved offering of HIV testing and prevention services, including PrEP, at STD specialty clinics would strengthen HIV prevention services. (See Box 3.)
- A significant number of people with HIV are unaware of their status or diagnosed in the later stages of their HIV disease. In 2018, 14%, or about 161,800 of people with HIV, were undiagnosed,² and nearly 21% of people diagnosed with HIV had a stage 3 (AIDS) classification at the time of diagnosis.⁷
- Despite the availability of PrEP since 2012, disparities in uptake persist.^{3,55,56} Though CDC estimates that 1.2 million people in the United States had indications for PrEP in 2018, only 18.1% were prescribed PrEP.⁷
- Despite overwhelming evidence that SSPs are an effective prevention tools, too few people at risk of HIV through injection drug use have access to them. According to one study,⁵⁷ people typically do not access SSPs if they are more than 10 miles from where they live. Yet nearly 80% (260.9 million people) of Americans live more than 10 miles from an SSP.⁵⁸ SSPs can reach people who would otherwise not get health care and connect them to life-saving services.



BOX 2

MISSED OPPORTUNITIES FOR HIV DIAGNOSIS

Substantial numbers of people at higher risk of HIV who had been unaware of their HIV infection experienced missed opportunities for earlier diagnosis. For example, in one study, approximately one-half of newly diagnosed gay and bisexual men and people who inject drugs who had been unaware of their infection until diagnosed during the study reported not being offered HIV testing by any health care provider despite having seen one in the past year.⁵³ Further, a retrospective study at an urban adolescent HIV clinic found that many youth living with recently diagnosed HIV had prior primary and acute care encounters within the health care system but did not receive an HIV test.⁵⁹

Other studies have pointed out missed opportunities by setting. For example, STD clinic patients represent a population at increased risk for HIV, yet data from nine STD clinics across the United States show that approximately three-quarters of STD clinic patients were not tested for HIV despite having a visit to the clinic in the past year.⁶⁰ Similarly, more than two-thirds of missed opportunities for HIV diagnoses in a Louisiana health care system occurred at nonprimary care health care visits including inpatient care, specialty care clinics, surgical specialties, ob-gyn visits, and emergency care facilities.⁶¹ In addition, a study from an infectious disease practice in New Jersey found that hospital emergency departments and subspecialty clinics were the two most common locations for missed testing opportunities, with between 37% and 45% of patients presenting with a new HIV diagnosis with an encounter in the institution in the year prior.⁶² Dental facilities present another opportunity to provide point-of-care HIV screening and testing.⁶³ Correctional institutions offer important opportunities to test for HIV and link those with HIV to post-release treatment services. Though CDC recommends opt-out screening in correctional settings,⁶⁴ studies have shown that opportunities for HIV diagnosis and linking HIV-positive inmates to community care after release are being missed in the majority of prison systems and jails.^{65,66}

[§] The term sexually transmitted infection (STI) refers to a virus, bacteria, fungus, or parasite that a person has acquired via sexual contact, whereas the term sexually transmitted disease (STD) refers to a recognizable disease state that has developed from an STI. Some stakeholders commonly use the term STI, and some commonly use the term STD.



BOX 3

OPPORTUNITIES FOR ENHANCED HIV PREVENTION SERVICES IN STD SPECIALTY CLINICS

These missed opportunities for HIV testing result in diagnosis delays, disease progression, and missed opportunities for HIV care and treatment. They also prolong the time a person is unaware of their infection, increasing the potential for HIV transmission. For care and treatment to reduce HIV incidence effectively, a high proportion of cases need to be diagnosed and treated soon after infection occurs. Improved testing coverage and frequency are needed to meet the goal of at least 95% of persons with HIV knowing their infection status and to reduce diagnosis delays and ultimately reduce HIV incidence in the United States.

STD specialty clinics play a vital role in reaching people at risk for HIV who are not engaged in HIV prevention programs or other health care services, including those who are uninsured and those who seek confidential services. In addition, STD specialty clinics serve a high proportion of racial and ethnic minorities, gay and bisexual men, and transgender people. STD specialty clinics are ideally positioned to reach populations at higher risk of HIV who could benefit from PrEP or PEP or reach people with HIV who are either unaware of their status or are not virally suppressed and could benefit from linkage to or reengagement in care.

Sources: CDC⁶⁷, Weston et al.⁶⁸, Seth et al.⁶⁹, Hoover et al.⁷⁰

SUMMARY OF OBJECTIVES

The following objectives are critical to achieving the goal of preventing new HIV infections:

- 1.1 Increase awareness of HIV
- 1.2 Increase knowledge of HIV status
- 1.3 Expand and improve implementation of effective prevention interventions, including treatment as prevention, PrEP, PEP, and SSPs, and develop new options
- 1.4 Increase the capacity of health care delivery systems, public health, and the health workforce to prevent and diagnose HIV

INDICATORS OF PROGRESS

Working together to pursue these objectives, the nation can achieve the following targets by 2025:

- | | |
|-------------|---|
| Indicator 1 | Increase knowledge of status to 95% from a 2017 baseline of 85.8% |
| Indicator 2 | Reduce new HIV infections by 75% from a 2017 baseline of 37,000 |
| Indicator 3 | Reduce new HIV diagnoses by 75% from a 2017 baseline of 38,351 |
| Indicator 4 | Increase PrEP coverage to 50% from a 2017 baseline of 12.6% |

OBJECTIVES AND STRATEGIES

Objective 1.1: Increase awareness of HIV

Nearly four decades into the HIV epidemic, too many people still lack essential information about HIV or hold misconceptions about the virus, including how it is prevented and transmitted. The resulting misperception of self-risk and perpetuation of HIV-related stigma and discrimination can deter people from learning their status, accessing prevention services, seeking or remaining in care, or supporting people who need diagnostic, prevention, care, or treatment services.

More must be done to increase HIV awareness among everyone, but especially among people, communities, and the health workforce where HIV is most heavily concentrated. Messaging must be clear, specific, consistent, and [culturally and linguistically appropriate](#) and must reflect today's scientific knowledge of HIV disease progression, its impact on community and individual health, the importance of early and sustained HIV treatment, and the health and prevention benefits of viral suppression. Once developed, the messaging should be broadly and persistently disseminated as educational campaigns using both traditional and social media delivered by trusted community members and community influencers.

School-based health education helps prevent HIV among adolescents by providing students with the knowledge and skills to help them be healthy and avoid HIV. HIV prevention education implemented in schools includes curricula that are medically accurate, developmentally appropriate, affirming, and culturally relevant with content and skills that target key behavioral outcomes and promote healthy sexual development. Suitable primary prevention approaches focused on youth should be age-appropriate, linguistically and culturally informed, community-centered, inclusive, stigma-reducing, and grounded in science and medicine. According to the American Academy of Pediatrics, developmentally appropriate and evidence-based education about human sexuality and sexual reproduction provided over time by pediatricians, schools, other professionals, and parents is important to help children and adolescents make informed, positive, and safe choices about healthy relationships, responsible sexual activity, and their reproductive health.⁷¹ As an example, primary prevention for adolescents who are not yet sexually active should encourage open and honest dialogue about the benefits of delaying the onset of sexual activity and other aspects of sexual health as appropriate. Primary prevention should be a part of comprehensive sexual education, particularly for youth, including abstinence or delayed initiation of sexual activity for those who are not yet sexually active, and non-judgmental and affirming information about safer sexual activity for those who are sexually active.

These efforts must engage people and organizations who shape and influence knowledge, attitudes, beliefs, and behaviors, particularly among populations at risk of HIV, as well as leverage digital strategies and new technologies to reach the highest number of people at relevant access points.

Strategies

- 1.1.1 Develop and implement campaigns and resources to provide education about comprehensive sexual health; HIV risks; options for prevention, testing, care, and treatment; and HIV-related stigma reduction.
- 1.1.2 Increase awareness of HIV among people, communities, and the health workforce in geographic areas disproportionately affected.
- 1.1.3 Integrate HIV messaging into existing campaigns and other activities pertaining to other parts of the syndemic, such as STIs, viral hepatitis, and substance use and mental health disorders.

Objective 1.2: Increase knowledge of HIV status

In addition to general knowledge about HIV, it is important for persons with HIV to receive a diagnosis (also known as knowledge of HIV status), which would allow them to take control of their health. Full implementation of CDC and USPSTF screening and testing guidelines is critical to increasing knowledge of status (see Box 4). Innovative models and approaches that expand access to and availability of testing in

various settings such as routine opt-out testing in clinical settings and self-testing are required. Early detection coupled with prompt linkage to care and immediate initiation of treatment is also critical and can lead to improved individual and community health outcomes.



BOX 4 HIV TESTING RECOMMENDATIONS

USPSTF Recommendation (2019)—USPSTF recommends that clinicians screen for HIV in adolescents and adults aged 15–65 years. Younger adolescents and older adults who are at increased risk of infection should also be screened. USPSTF also recommends that clinicians screen for HIV infection in all pregnant women, including those who present in labor or at delivery with unknown HIV status. [Read the recommendation.](#)

CDC Recommendations (2006)—CDC recommends that everyone aged 13–64 years get tested for HIV at least once as part of routine health care. For those with specific risk factors, CDC recommends testing at least annually. [Read the recommendations.](#)

Expansion of the status neutral approach to HIV services allows for ongoing engagement in HIV prevention, care, and treatment regardless of a person’s HIV status (see Box 5). HIV testing serves as the entry point to services. In addition, people are assessed for and engaged in continuous care and supportive services if needed to improve health and prevent new infections (see Figure 7). People whose HIV test results are negative are informed of and linked to the HIV prevention options that work best for them, retested as needed, and engaged in the broader system of health care to address other health needs. People whose HIV test results are positive are immediately linked to care and treatment. It also is necessary to provide partner services such as confidentially notifying partners of a possible HIV and/or STI exposure; offering partners HIV and STI testing and treatment or PrEP, if indicated; and linking to a range of medical, prevention, and psychosocial services for co-occurring conditions, if needed.

Strategies

- 1.2.1 Test all people for HIV according to the most current USPSTF recommendations and CDC guidelines.
- 1.2.2 Develop new and expand implementation of effective, evidence-based, or evidence-informed models for HIV testing that improve convenience and access.
- 1.2.3 Incorporate a status neutral approach to HIV testing, offering linkage to prevention services for people who test negative and immediate linkage to HIV care and treatment for those who test positive.
- 1.2.4 Provide partner services to people diagnosed with HIV or other STIs and their sexual or needle-sharing partners.



BOX 5 STATUS NEUTRAL APPROACH TO HIV

Adoption of a status neutral approach to HIV services—in which HIV testing serves as an entry point to services regardless of positive or negative result—can improve testing as well as prevention and care outcomes. In this approach, people diagnosed with HIV are linked to care and treatment services as quickly as possible to achieve and maintain viral suppression, which both protects their own health and prevents transmission.




Figure 7. New York City's HIV status neutral prevention and treatment cycle.⁷²
Source: Adapted from Myers et al.⁷³

Objective 1.3: Expand and improve implementation of effective prevention interventions, including treatment as prevention, PrEP, PEP, and SSPs, and develop new options

Today, a range of highly effective prevention methods are available for use in combination or on their own. However, they do not yet reach everyone who needs them. Scaling up combinations of scientifically proven, cost-effective interventions targeted to the right populations in the right geographic areas is key to preventing new HIV infections. Especially important is scaling up highly effective, biomedical interventions: treatment as prevention (U=U), PrEP, and PEP, along with other highly effective prevention interventions including abstinence, correct and consistent condom usage, HIV and viral hepatitis testing, SSPs and harm reduction services, and behavioral health services.^{49,74,75,76,77}

These interventions must be available to people who need them in a variety of traditional health care and public health settings as well as nontraditional settings. Public health and health care systems can better meet the HIV prevention needs of the people they serve by developing or adopting culturally competent and linguistically appropriate approaches and policies to service design and delivery. Examples of interventions include the development and adoption of models that allow for low-barrier access to prevention and supportive services such as expanded service hours, drop-in appointments, telehealth, peer navigators, community health workers, and co-located service delivery.⁷⁸ Schools can offer on-site sexual health services through their own health care infrastructure, such as school-based health centers (SBHCs) and school nurses, or can establish referral systems to community partners to provide services, such as periodic, school-wide HIV screening events or mobile clinics. Policy and other systemic changes can support the expansion or improvement of these prevention interventions, and can often be cost-neutral or cost-saving, as resources are realigned and services are provided at focused hours and delivery is optimized to those seeking assistance. For example, structural barriers such as state or local laws or policies may need to be reviewed and revised to facilitate expanded access to HIV prevention services, such as permitting SSPs or expanding prescribing authority for PrEP and PEP.

Ongoing implementation research on how best to use new and existing HIV prevention tools is needed, as is continued research into new tools that make HIV prevention more convenient and accessible. This must include further research on biomedical interventions that simplify implementation, such as long-acting, extended-release tools that can protect against HIV infection without daily pills, as well as non-systemic tools that expand user options such as lubricant- or douche-based microbicides or multi-purpose tools that might protect women from both HIV and pregnancy. Research is also needed regarding strategies to most effectively integrate such tools into HIV prevention services when they become available. Continued research into other prevention tools is also needed, including antibody mediated protection strategies, effective vaccines, and behavioral and social-structural interventions.

Strategies

- 1.3.1 Engage people at risk for HIV in traditional public health and health care delivery systems, as well as in nontraditional community settings
- 1.3.2 Scale-up treatment as prevention/U=U by diagnosing all people with HIV, as early as possible, and engaging them in care and treatment to achieve and maintain viral suppression.
- 1.3.3 Make HIV prevention services, including condoms, PrEP, PEP, and SSPs, easier to access and support continued use.
- 1.3.4 Implement culturally competent and linguistically appropriate models and other innovative approaches for delivering HIV prevention services.
- 1.3.5 Support research into the development and evaluation of new HIV prevention modalities and interventions for preventing HIV transmissions in priority populations.

Objective 1.4: Increase the capacity of health care delivery systems, public health, and the health workforce to prevent and diagnose HIV

Expanding awareness, access, uptake, and adherence to effective HIV prevention interventions and improving availability of HIV testing for people with undiagnosed infection or ongoing risk of acquisition are actions that fall largely under the purview of the health care and public health systems. Therefore, steps must be taken to strengthen and expand capacity to ensure these services are more commonly available in clinical and nonclinical settings including primary care, community-based organizations, emergency departments, pharmacies (see Box 6), Title X family planning sites, STD specialty clinics (see Box 3), substance use disorder treatment facilities, correctional settings, and other settings.

One step involves training all staff, ranging from those performing administrative duties to those delivering direct care, on trauma-informed care, cultural competency, stigma and discrimination, and unrecognized bias. Health care services that are respectful of and responsive to the health beliefs, practices, and cultural and linguistic needs of diverse patients can also help bring about positive health outcomes.⁷⁹ Another step involves providing resources, incentives, training, and technical assistance to organizations to expand workforce and systems capacity especially in areas with limited availability of prevention and other health care and supportive services.⁸⁰

These efforts must seek to expand the number, variety, diversity, and distribution of health care providers who routinely provide HIV testing, prevention counseling, and linkage to specialty care. A recent study showed that a low proportion of primary care providers were familiar with PEP and PrEP.⁸¹ In some settings, these efforts require addressing the “purview paradox,” a contradiction in which primary care physicians and HIV specialists sometimes consider PrEP to be beyond their purview.⁸² Thus, HIV prevention and testing must become the purview of providers of all types who care for patients who may be at risk. Further, health care providers in high HIV prevalence jurisdictions must understand the relationship of epidemiological context and HIV acquisition. In these jurisdictions, providers may be encouraged to offer universal opt-out HIV testing and integrate PrEP screening as a part of routine care for all clients.



BOX 6

PHARMACISTS’ ROLES IN HIV PREVENTION AND CARE

Pharmacists’ knowledge and accessibility in nearly every urban and rural community can be leveraged as part of a comprehensive HIV prevention and care strategy to expand access to care and improve population health. As trusted health care professionals, pharmacists develop a strong rapport with patients and may be the key to address current disparities in PrEP-prescribing patterns as well as serve as an essential liaison between patients and other members of the multidisciplinary care team.⁸³ Pharmacists and community pharmacies can also be utilized to expand rapid, point-of-care HIV testing in communities.⁸⁴ In addition, studies have shown that engaging pharmacists as a key player in a care team can increase adherence to ART and maintain viral suppression.⁸⁵

Strategies

- 1.4.1 Provide resources, incentives, training, and technical assistance to expand workforce and systems capacity to provide or link clients to culturally competent and linguistically appropriate HIV testing, prevention, and supportive services especially in areas with shortages that are geographic, population, or facility based.
- 1.4.2 Increase the diversity of the workforce of providers who deliver HIV prevention, testing, and supportive services.
- 1.4.3 Increase the inclusion of paraprofessionals on prevention teams by advancing training, certification, supervision, financing, and team-based care service delivery.
- 1.4.4 Include comprehensive sexual health information in curricula of medical and other health workforce education and training programs.



Goal 2: Improve HIV-Related Health Outcomes of People with HIV

THE OPPORTUNITY

Starting and staying on HIV treatment as soon as possible following HIV diagnosis is necessary for all people with HIV⁸⁶ to improve health outcomes and to prevent HIV transmissions.^{87,88} People who start HIV treatment early and remain adherent to antiretroviral medications can live a normal lifespan. Improving the health of people with HIV requires continued focus on the HIV continuum of care to identify gaps and disparities at each step of the continuum to target resources and interventions (see Figure 8).

The series of steps a person with HIV takes from diagnosis through their successful treatment with HIV medication.




Figure 8. The HIV care continuum outlines the steps that people with HIV take from diagnosis to achieving and maintaining viral suppression. Source: HIV.gov.⁸⁹

One common gap is the lack of understanding about the personal and public health benefits of entering treatment immediately and achieving and maintaining viral suppression. Increasing HIV education and available treatment along with strengthening relationships between patients and providers can play an even larger part in supporting people with HIV to begin, or reengage in, care and treatment and improve long-term

health outcomes. Developing and expanding partnerships between providers of HIV specialty care and other providers (such as primary care and other health care providers as well as community organizations, health departments, jails and prisons, and others) can leverage existing resources, allowing for seamless transitions between each step of the continuum from diagnosis to achieving and maintaining viral suppression. Implementing evidence-based interventions, innovative uses of technology, and systems changes can support rapid linkage to care and maintenance in treatment for people with HIV. In addition, government, academic, and pharmaceutical industry research has provided simpler, more easily tolerated therapies than the initial generation of effective antiretroviral therapies. Continued advances such as long-acting injectables could result in the introduction of new HIV treatments during the course of this 5-year plan. These new options could help address challenges with adherence to a daily pill regimen.

Several approaches exist to support treatment initiation and adherence as well as retention in care across the continuum, including:

- **Rapid start programs.** Programs focusing on the immediate (ideally same day or within 7 days after diagnosis) initiation of ART have demonstrated success and are expanding in communities across the nation. Such “rapid start” or “red carpet” programs require structural or other changes to improve linkage to care, care coordination, patient navigation, adequate staffing, specialized services, and clinical provider evaluation.
- **Evidence-based strategies.** Every year evidence-informed best practices are added to the compendia of recommended interventions designed to improve treatment adherence and retention in care. Although interventions are often not a one-size-fits-all approach, health departments, clinics, and community organizations have additional tools to implement and receive a wide-range of adaptations that have worked in different settings, different population sizes, and for specific populations. Increasing the use of evidence-based strategies and best practices to reengage people who have fallen out of care, and people never in care, is necessary. Community input coupled with the strategies and interventions that have proven effective are necessary to reach populations out of care and help them achieve viral suppression.
- **Health literacy.** Limited health literacy is associated with poorer health outcomes.⁹⁰ At all levels further effort is needed to construct organizations, institutions, systems, and a workforce that embrace and implement the concepts and principles of health literacy. Efforts to create more health-literate public and private health systems at the federal, state, and local levels will help patients understand the health care system and the importance of HIV prevention, care, and treatment, and the benefits of viral suppression. This understanding can empower people to participate in these systems and may help to address the pervasive issues of medical mistrust among minority populations. Patient education is a necessary aspect of people-centered care, but it requires systems and providers to end the use of jargon, take the time to educate and explain in plain language, alter websites and brochures, use social media differently, and consider other culturally appropriate ways to deliver key information. Understanding HIV, the importance and benefits of treatment, and the risks of transmission to others can also lead to less stigma and shame, which in turn can lead to increased interactions with the health system and positive health outcomes.⁹¹ Efforts to increase health literacy can also aid in addressing the mistrust of the medical system prevalent among many minority groups because of the historical systemic racism in many health care settings.



GOAL 2: IMPROVE HIV-RELATED HEALTH OUTCOMES OF PEOPLE WITH HIV

Objectives

- 2.1 Link people to care immediately after diagnosis and provide low-barrier access to HIV treatment
- 2.2 Identify, engage, or reengage people with HIV who are not in care or not virally suppressed
- 2.3 Increase retention in care and adherence to HIV treatment to achieve and maintain long-term viral suppression
- 2.4 Increase the capacity of health care delivery systems, public health, and the health workforce to serve people with HIV

- **Comprehensive array of clinical and support services.** Current systems of HIV care and treatment have produced tremendous results, and the nation has more providers treating people with HIV than ever before. Today, people with HIV who are on treatment are living longer and healthier lives; and more than one-half of the people with HIV in the United States are over age 50. Researchers and clinicians are identifying and providing services to address the comorbidities experienced by those aging with HIV as well as people with HIV across the entire lifespan whose health can be impacted by noncommunicable comorbidities or coinfections. Other key population groups, such as youth, transgender people, people with substance use disorders, justice-involved individuals, or people experiencing homelessness, require different combinations of tailored services to help improve their health outcomes.⁹² Work continues to scale up evidence-based and evidence-informed programs that provide enhanced case and care management for people with HIV specific to their comorbidities or co-occurring conditions such as homelessness, food insecurity, and lack of employment.
- **Capacity of the health care delivery system.** As providers engage and reengage people in care and implement rapid start models, the numbers of people in care will increase. However, workforce needs may not be able to keep pace. The existing highly skilled and dedicated workforce combined with a growing number of Federally Qualified Health Centers treating people with HIV are key to ensuring positive health outcomes. There is an opportunity to examine ways to restructure staff and clinic workflows, implement technological solutions, enhance quality improvement programs, consolidate paperwork requirements, and examine task sharing to create new efficiencies and revamp the ability to use peers in key places along the HIV care continuum. Continuing to find innovative ways to encourage clinical and nonclinical providers to specialize in HIV care and treatment and engaging primary care providers in care and treatment of HIV, viral hepatitis, and STIs will remain important.
- **Meaningful involvement of people with HIV in program design and implementation.** People with HIV are central to the response to the epidemic and must be included in all elements of programming to achieve the HIV Plan's goals by 2030. People with HIV must be included in program design and implementation, quality improvement initiatives, social media campaigns, engaged as peers in prevention and care services, and involved in large-scale structural and policy initiatives. COVID-19 has presented opportunities for engaging people with HIV and communities in new and different ways and program implementers must continue to create mechanisms for the meaningful engagement of interested individuals.

CHALLENGES

To achieve the goal of improving HIV-related health outcomes, the following challenges must be addressed:

- Health care capacity and workforce shortages in critical geographic areas such as the southern United States and rural areas present challenges to expanding access to HIV care and treatment. These shortages will limit the ability to improve health outcomes for people with HIV. The capacity to provide quality care and treatment is threatened if new technology and new approaches are not embraced.
- Intersecting conditions of stigma, mental health challenges, substance use disorders, and health care lapses due to incarceration require scaling up evidence-based and evidence-informed approaches to care and treatment as well as interventions to engage people out of care, often because of one or more of those conditions. Models of trauma-informed care, which acknowledge the effects of trauma in a person's life and work explicitly not to retraumatize, are still being developed and scaled up around the country.
- HIV-related stigma and other forms of stigma associated with people with HIV continue to impede optimal health outcomes for people with HIV. Increasing cultural humility training among HIV clinicians and even the entire staff of clinics and organizations can lead to increased care engagement and improved health outcomes.
- New and innovative health care delivery strategies and therapeutics are needed to better reach, support, and retain people most vulnerable to non-adherence or dropping out of care. These options are needed

to improve HIV treatment outcomes, reduce inequities, and help to prevent onward transmission of HIV. Creative health care delivery strategies implemented by multidisciplinary and/or multisectoral teams are imperative to better reach people with HIV who have not benefited from advances in HIV treatment and care. Implementation research conducted in concert with changes in delivery strategies will enable generalizable knowledge to share with other similar service provision settings. In addition, development of new drugs for daily ART and innovation in ART delivery, such as long-acting or extended-release injectable drugs, or the use of broadly neutralizing antibodies to treat HIV infection could provide greater options for addressing care and treatment challenges experienced by some people with HIV.

- More diverse community input is needed to inform program implementers' tailoring of evidence-based strategies to meet the needs of particular communities and populations. Engagement of people with HIV has increased over the years and enhanced our understanding of effective interventions and added to our base of implementation science; however, more must be done to understand the lived experiences and needs of communities.

SUMMARY OF OBJECTIVES

A concerted national effort to engage people with HIV in care is essential to achieving the HIV Plan's vision. The following steps are critical to achieving success:

- 2.1 Link people to care immediately after diagnosis and provide low-barrier access to HIV treatment
- 2.2 Identify, engage, or reengage people with HIV who are not in care or not virally suppressed
- 2.3 Increase retention in care and adherence to HIV treatment to achieve and maintain long-term viral suppression
- 2.4 Increase the capacity of the public health, health care delivery systems, and the health care workforce to effectively identify, diagnose, and provide holistic care and treatment for people with HIV

INDICATORS OF PROGRESS

Working together to pursue these objectives, the nation can achieve the following targets by 2025:

- | | |
|-------------|---|
| Indicator 5 | Increase linkage to care within 1 month of diagnosis to 95% from a 2017 baseline of 77.8% |
| Indicator 6 | Increase viral suppression among people with diagnosed HIV to 95% from a 2017 baseline of 63.1% |

OBJECTIVES AND STRATEGIES

Objective 2.1: Link people to care rapidly after diagnosis and provide low-barrier access to HIV treatment

Achieving improved health outcomes for people with HIV begins with ensuring they are promptly linked to effective HIV care and treatment upon diagnosis. Linkage to HIV care and treatment immediately or as early as possible following HIV diagnosis leads to faster time to viral suppression, increased rates of retention in care and ongoing viral suppression, and reduction in transmission risk.^{93,94,95} Programs must continue to build capacity and shrink the amount of time between diagnosis and linkage to care so that immediate linkage to care becomes the standard across the United States, allowing people to begin receiving care and treatment within hours or days of their diagnosis no matter where they live. This may require that some clinics and health departments work to reduce facility-based, government-based, workforce, or administrative barriers to initiating care and treatment. Red carpet and warm-handoff programs provide low-barrier access by linking newly diagnosed people to care

and treatment services, often within the same day.^{96,97} For example, these programs, which often integrate robust navigation services, may schedule medical appointments on behalf of the patient, drive newly diagnosed people who lack transportation from an HIV testing site to a trusted clinic, or help people who need assistance complete required forms and paperwork.

Strategies

- 2.1.1 Increase linkage to HIV medical care within 30 days of diagnosis, as early as the same day.
- 2.1.2 Provide same-day initiation or rapid start (within 7 days) of antiretroviral therapy for those who are able to take it.

Objective 2.2: Identify, engage, or reengage people with HIV who are not in care or not virally suppressed

Although improvements have been made over time, only 58%⁷ of people with diagnosed HIV are retained in care in 2018. In addition, 24% of people with HIV who are not receiving care account for 43% of new infections.⁷ This population often needs highly tailored approaches to identify, conduct outreach, ascertain barriers to care, and create individualized care plans to facilitate entry into care, followed by navigation and other services to support retention in care, such as short- or long-term housing assistance, benefits counseling across the social services spectrum, and employment counseling. New solutions must be identified to engage and reengage populations that, to date, systems have been unsuccessful in reaching and retaining in care. Feedback and evaluations of services from people with HIV is critical to understanding and improving how services are received by those who need them the most.

Data-to-care models based on solid, interwoven data points, and other evidence-based strategies focused on finding people not in care and people who are not yet virally suppressed, are proven strategies to reengage people over the long term.⁹⁸ Disparate data systems must first be linked to identify people who have tested HIV positive but do not have recent indicators of quality care, people who have fallen out of care, people in care who lack timely prescription refills, and people in care who have not achieved or maintained viral suppression. Entering into formal data sharing agreements ensures that the uses of the data, responsibilities, and protections are clearly delineated for all parties. Such agreements are needed among state public health surveillance systems, state and local health departments, tribes, tribal organizations, urban Indian organizations, the RWHAP, federally funded health centers of all types, community-based organizations, HOPWA programs, Medicaid, Departments of Corrections, pharmacies and pharmacy benefits managers, and other components of the health system serving people with HIV in a geographic area. A goal of data sharing agreements is to reduce administrative burden on providers as well as individuals, avoiding redundant intakes, increasing efficiency, and preparing providers to work alongside clients to develop comprehensive treatment plans without delay.

Strategies

- 2.2.1 Expand uptake of data-to-care models using data sharing agreements, integration and use of surveillance, clinical services, pharmacy, and social/support services data to identify and engage people not in care or not virally suppressed.
- 2.2.2 Identify and address barriers for people who have never engaged in care or who have fallen out of care.

Objective 2.3: Increase retention in care and adherence to HIV treatment to achieve and maintain long-term viral suppression

People with HIV need ongoing support to stay in care and maintain the adherence to ART that is needed to achieve and maintain viral suppression.⁹⁹ Approaches to increase retention in care include higher levels of personal contact with a patient navigator or community health worker to ensure care receipt; reminders about appointments and calls to discuss why appointments were missed; patient navigation services designed to help patients identify, apply for, and receive necessary services to bolster medical care; medical case management; financial incentives; and low-threshold care including walk-in appointments and on-site pharmacies.^{100,101} Among

adherence interventions are those designed to ensure the efficiency of receiving and taking medications such as 90-day prescriptions, options for medication pick-up or receipt by mail, and use of technology such as medication reminder apps, as well as adherence counseling. Other interventions must address common barriers to adherence and retention, such as providing co-located treatment for HIV and mental health and substance use disorders.

Ongoing research in a variety of disciplines is also needed to improve care retention, medication adherence, and sustained viral suppression. Research topics include next-generation therapeutics that are longer-acting, less toxic, and have fewer side effects and complications, as well as behavioral and social sciences to better understand and address barriers to treatment uptake and adherence and to address disparities. Biomedical, behavioral, and implementation research approaches can be combined to improve viral suppression, reduce HIV transmission, and improve health for all affected populations. Basic, translational, and clinical research can increase understanding of HIV-related comorbidities, co-infections, and complications, which can interfere with retention, adherence, or viral suppression.

New and differentiated models of care, especially those that integrate HIV prevention, care, and supportive services, alongside broader structural interventions, must be tailored and implemented for priority populations. Many populations such as youth transitioning from pediatric to adult care, individuals who do not have consistent and stable housing, and individuals being released from correctional facilities need well-coordinated interventions spanning systems, providers, and payers and must address structural, medical, behavioral, and support service concerns.

Strategies

- 2.3.1 Support the transition of health care systems, organizations, and clients to become more health literate in the provision of HIV prevention, care, and treatment services.
- 2.3.2 Develop and implement effective, evidence-based, or evidence-informed interventions and supportive services that improve retention in care.
- 2.3.3 Develop and implement effective, evidence-based, or evidence-informed treatment interventions, such as HIV telemedicine, accessible pharmacy services, community health workers and peer navigators, and others, that improve convenience and access, facilitate adherence, and increase achievement and maintenance of viral suppression.
- 2.3.4 Support ongoing clinical, behavioral, and other research to support retention in care, medication adherence, and durable viral suppression.

Objective 2.4: Increase the capacity of the public health, health care delivery systems, and the health care workforce to effectively identify, diagnose, and provide holistic care and treatment for people with HIV

Increasing viral suppression requires expanded capacity of public health, health care and support service delivery systems, and the health workforce to be flexible and responsive to the needs of people with HIV. Increasing the diversity of providers offering HIV prevention and care services is one important capacity-building approach. In addition, publicly funded organizations can increase the diversity of their workforce and provide training to ensure culturally competent care and knowledge of best practices for caring for people from diverse backgrounds.¹⁰² Health care and support systems can also take advantage of different types of health professionals such as nurses, advanced practice providers, pharmacists, and behavioral health specialists to ensure that any workforce shortages can be addressed. Innovative staffing models can also build capacity to better meet the needs of people with HIV including the use of community health workers, linkage to care and reengagement specialist teams, task sharing, integrated care teams, and use of peer mentors.¹⁰³ In addition, sustained continuous quality improvement programs must be utilized to ensure up-to-date and high-quality care is being provided by integrated and diverse care teams.

In addition to the RWHAP, patient-centered medical homes and health homes create opportunities to address medical and support service needs of people with HIV through coordinated, team-based, and accessible services including co-location of services providing behavioral, substance use, reproductive, and other-related health care services. Similar to HIV prevention, expanding care and treatment capacity must also include delivery of additional resources, incentives, training, and technical assistance to existing systems as well as development of new systems in areas with limited availability. For example, establishing new partnerships and advancing telehealth arrangements to expand access to professionals with specialized backgrounds should be explored to increase access to services in geographically underserved areas. The design of programs to reach and engage people out of care, people never in care, and people who are challenged to stay in care may require novel approaches, services, and partnerships to address issues of trauma, poverty, and associated conditions that are obstacles to care. Systems should also offer low-threshold capacity-building resources to organizations led and staffed by local members of the priority populations to increase their ability to apply for and receive grants and foundation funds to increase the number of services being provided in and by affected communities.

Strategies

- 2.4.1 Provide resources, value-based and other incentives, training, and technical assistance to expand workforce and systems capacity to provide or link clients to culturally competent and linguistically appropriate care, treatment, and supportive services especially in areas with shortages that are geographic, population, or facility based.
- 2.4.2 Increase the diversity of the workforce of providers who deliver HIV and supportive services.
- 2.4.3 Increase inclusion of paraprofessionals on teams by advancing training, certification, supervision, reimbursement, and team functioning to assist with screening/management of HIV, STIs, viral hepatitis, and substance use disorder and other behavioral health conditions.



Goal 3: Reduce HIV-Related Disparities and Health Inequities

THE OPPORTUNITY

Advances in HIV prevention, testing, care, treatment, and supportive services have led to significant declines in new HIV transmissions and deaths. They also make it possible for the nation to envision ending the HIV epidemic. However, realizing this vision requires that every person across the United States with or at risk for HIV has access to high-quality and culturally competent prevention, diagnostic, care, treatment, and supportive services that are non-stigmatizing, non-discriminatory, inclusive, and responsive to their needs. In order to successfully achieve the goal of ending the HIV epidemic, issues such as discrimination and systemic racism that contribute to differences in health care quality and access, as well as access to other necessities such as housing and behavioral and substance use services, and lead to ongoing disparities among racial, ethnic, and sexual and gender minority populations, must be addressed.

Reducing these disparities entails focusing on the needs of disproportionately affected populations, supporting racial justice, combating HIV-related stigma and discrimination, providing leadership and employment opportunities for people with or at risk for HIV, and addressing social determinants of health and co-occurring conditions to reduce health inequities and disparities. Therefore, the HIV Plan fully recognizes that the national HIV goals can only be achieved through collaborative efforts at the federal, state, tribal, and local levels that focus on reducing HIV-related disparities and by ongoing commitment to understand and address the central factors that create HIV inequities.

In recent years, the nation and individual states have made progress in the area of HIV-related disparities. For example:

- The RWHAP significantly reduced viral suppression disparities among client populations, particularly women, transgender people, youth, Blacks, and people with unstable housing. Overall, 88% of clients receiving medical care in the RWHAP were virally suppressed in 2019.⁹ From 2010 to 2019, the gap between male and female clients decreased from nearly 5 percentage points to <1 percentage point. In addition, the gap between male and transgender clients decreased from 9 percentage points to 5 percentage points. Similarly, the disparity between viral suppression rates in Black clients and white clients was 13 percentage points in 2010 but 7 percentage points in 2019.^{9,10} HRSA and its RWHAP grant recipients have continued to use these data to drive programs and decision-making.
- From 2015 to 2018 the United States saw reductions of disparities in the rates of new HIV diagnoses among gay and bisexual men, Black gay and bisexual men, and Black women.
- Since 2014, at least five states (CA, CO, IA, MI, NC) have modernized their HIV criminal exposure laws. Changes have included removing HIV prevention issues from the criminal code and including them instead under disease control regulations, requiring intent to transmit or actual HIV transmission, or providing for defenses for taking measures to prevent transmission.



GOAL 3: REDUCE HIV-RELATED DISPARITIES AND HEALTH INEQUITIES

Objectives

- 3.1 Reduce HIV-related stigma and discrimination
- 3.2 Reduce disparities in new HIV infections, in knowledge of status, and along the HIV care continuum
- 3.3 Engage, employ, and provide public leadership opportunities at all levels for people with or at risk for HIV
- 3.4 Address social determinants of health and co-occurring conditions that exacerbate HIV-related disparities

CHALLENGES

Ongoing HIV-related disparities persist across populations and geographic areas in the United States (see Priority Populations section). To achieve the goal of reducing HIV-related disparities and health inequities, the following challenges, among others, must be addressed:

- The prevalence of HIV is more than 150 times higher in gay, bisexual, and other men who have sex with men and in transgender women than heterosexual men and women.¹⁰⁴
- One-half of all new HIV infections occurred in the southern United States in 2018, despite only accounting for 38% of the U.S. population.²
- Among the estimated 161,800 people with undiagnosed HIV infection, 42% are among Blacks, 28% among Latinos, 24% among whites, and 6% among other racial and ethnic groups.²
- Disparities are also evident in the proportion of people with HIV with viral suppression; in 2018, 60% of Blacks, 64% of Latinos, and 71% of whites with diagnosed HIV were virally suppressed.⁷ Further, among RWHAP clients, transgender clients were virally suppressed at a rate of 81.8%, which is lower than the national average of 87.1% for all RWHAP clients.¹⁰⁵
- Significant disparities exist in PrEP uptake by age, race, gender, and geographic location.^{55,56} In 2018, PrEP coverage among whites was seven times that among Blacks and four times that among Latinos.⁵ In addition, only 7% of women with indications for PrEP received a prescription in 2018 versus 21% of males. By age, the lowest level of PrEP coverage was among people aged 16–24 years (12%).⁵

Research to better understand and address such disparities and inequalities—including through community-based participatory research methods—can help improve HIV testing and engagement and retention in prevention and care services, and can enhance the health and well-being of people with or at risk for HIV in underserved and marginalized communities.

Another consideration is appropriately responding to HIV among groups that represent a small share of both the population and of HIV infections. Although it is vital to focus national efforts in communities with the highest burden, HIV prevention, care, and treatment must continue to be supported in localities with concentrations of groups such as Asian Americans and Pacific Islanders and American Indians/Alaska Natives, and informed by the best available data.

A Focus on Health Inequities

Certain racial and ethnic minority groups have higher rates of HIV incidence, prevalence, poor health outcomes (lower viral suppression), and mortality, compared with rates for non-Hispanic whites.¹⁰⁶ Health disparities can stem from inequities in the social determinants of health and highlight the need to focus on not only HIV prevention and care efforts, but also how programs, practices, and policies affect racial and ethnic minority communities. Racial and ethnic minority groups are more likely to be uninsured compared to non-Hispanic whites,¹⁰⁷ limiting their access to health care. Sexual and gender minorities also face health inequities. Sexual and gender minorities have lower levels of health insurance and access to regular health care compared to their heterosexual counterparts.^{30,31} Barriers to health care access include lack of transportation and childcare, inability to take time off from work, communication and language barriers, racism, discrimination, and lack of trust in health care providers.¹⁰⁸

The HIV Plan recognizes the importance of addressing social determinants of health to improve health outcomes for racial, ethnic, and sexual and gender minority groups. By working to establish policies and programs that positively influence social and economic conditions and by supporting changes in individual behavior, health can be improved and sustained, and disparities reduced. Improving the conditions in which we live, learn, work, play, age, and worship and the quality of our relationships will create a healthier population, society, and workforce.¹⁰⁹ Application of a “health in all policies” strategy, a cross-sector collaborative approach to integrating health into policies and programs^{110,111} to close the health gaps, can be implemented across all areas and levels of government and in the community to foster achievement of these aims.

SUMMARY OF OBJECTIVES

The following objectives are critical to reducing HIV-related disparities and health inequities:

- 3.1 Reduce HIV-related stigma and discrimination
- 3.2 Reduce disparities in new HIV infections, in knowledge of status, and along the HIV care continuum
- 3.3 Engage, employ, and provide public leadership opportunities at all levels for people with or at risk for HIV
- 3.4 Address social determinants of health and co-occurring conditions

INDICATORS OF PROGRESS

Working together to pursue these objectives, the nation can achieve the following targets by 2025:

- | | |
|-------------|---|
| Indicator 7 | Decrease stigma among people with diagnosed HIV by 50% from a 2018 baseline median score of 31.2 on a 10-item questionnaire |
| Indicator 8 | Reduce homelessness among people with diagnosed HIV by 50% from a 2017 baseline of 9.1% |

In addition to these indicators, the HIV Plan identifies a disparities indicator to measure progress toward reducing significant HIV-related disparities. Core indicator 6 on viral suppression serves as this disparities indicator and is stratified by each of the priority populations identified in the HIV Plan:

Indicator 6a	Increase viral suppression among MSM diagnosed with HIV to 95% from a 2017 baseline of 66.1%
Indicator 6b	Increase viral suppression among Black MSM diagnosed with HIV to 95% from a 2017 baseline of 58.4%
Indicator 6c	Increase viral suppression among Latino MSM diagnosed with HIV to 95% from a 2017 baseline of 64.9%
Indicator 6d	Increase viral suppression among American Indian/Alaska Native MSM diagnosed with HIV to 95% from a 2017 baseline of 67.3%
Indicator 6e	Increase viral suppression among Black women diagnosed with HIV to 95% from a 2017 baseline of 59.3%
Indicator 6f	Increase viral suppression among transgender women in HIV medical care to 95% from a 2017 baseline of 80.5%
Indicator 6g	Increase viral suppression among people who inject drugs diagnosed with HIV to 95% from a 2017 baseline of 54.9%
Indicator 6h	Increase viral suppression among youth aged 13-24 diagnosed with HIV to 95% from a 2017 baseline of 57.1%

OBJECTIVES AND STRATEGIES

Objective 3.1: Reduce HIV-related stigma and discrimination

Many people with HIV experience stigma and discrimination because of their HIV status. Stigma is an attitude of disapproval and discontent toward a person or group because of the presence of an attribute perceived as undesirable. Discrimination is often a consequence of stigma, occurring when unfair and often unlawful actions are taken against people based on their belonging to a particular stigmatized group. HIV stigma and discrimination can pose complex barriers for people with or at risk for HIV, preventing them from seeking prevention tools, learning their HIV status, and accessing medical care, treatment, and supportive services. Stakeholders and organizations from all sectors of society, including government, faith communities, businesses, schools, and others, must work to combat stigma and discrimination in order to reduce new transmissions and improve health outcomes for people with HIV.

HIV-specific criminal laws perpetuate HIV-related stigma and discrimination. Some of these laws that criminalize behavior pose low or no risk for transmitting HIV and apply regardless of actual HIV transmission. Agreement on the need to reform HIV criminalization laws is increasing. Such efforts must ensure that all state and federal criminal laws and policies regarding HIV transmission and prevention are scientifically based and reflect well-tested and effective public health strategies, and that legislators, prosecutors, and people in law enforcement have an accurate understanding of HIV transmission risks (see Box 7).

Discriminatory practices and minority stress also play a role in health outcomes.¹³⁷ Public health and health care systems should seek to be respectful of and responsive to the health beliefs, practices, and cultural and language needs of diverse patients.¹¹² At the community level, stakeholders and advocates should be equipped with knowledge and tools to address misconceptions and change norms that are associated with HIV-related stigma and discrimination. At the individual level, multiple approaches to address interpersonal and internalized stigma should be available to people with or at risk for HIV as well as their family, friends, health care providers, and others.

HIV-related stigma and discrimination and their effects on people with or at risk for HIV should not be viewed in a silo. They come in different forms and are often complicated when people also experience stigma and discrimination related to, among other identities or experiences, race and ethnicity, sexual orientation or sexual behavior, gender identity, substance use, mental health, homelessness, socioeconomic circumstance, justice involvement, immigration status, or sex work.^{92,113} Additional research, innovative solutions, and replication of global efforts to address the drivers, facilitators, and manifestations of stigma are needed.¹¹⁴ These solutions should be integrated into the delivery of services that are responsive and sensitive to the unique needs of populations that face intersectional stigmas and intersectional discrimination.

Strategies

- 3.1.1 Strengthen enforcement of civil rights laws (including language access services and disability rights), reform state HIV criminalization laws, and assist states in protecting people with HIV from violence, retaliation, and discrimination associated with HIV status, homophobia, transphobia, xenophobia, racism, and sexism.
- 3.1.2 Ensure that health care professionals and front-line staff complete education and training on stigma, discrimination, and unrecognized bias toward populations with or at risk for HIV.
- 3.1.3 Support communities in efforts to address misconceptions and reduce HIV-related stigma and other stigmas that negatively affect HIV outcomes.



BOX 7

STATE HIV CRIMINALIZATION LAWS

According to the Centers for Disease Control and Prevention (CDC), as of 2020, [37 states have laws that criminalize HIV exposure](#). Some of these laws criminalize [behavior that cannot transmit HIV](#) and apply regardless of actual transmission (see Figure 9).

CDC assessed the laws for the 50 states and the District of Columbia and grouped them into five categories:

1. HIV-specific laws that criminalize or control behaviors that can potentially expose another person to HIV.
2. STD/communicable/infectious disease-specific laws that criminalize or control behaviors that can potentially expose another person to those diseases, which might include HIV.
3. Sentence enhancement laws specific to HIV that do not criminalize a behavior but increase the sentence length when a person with HIV commits certain crimes.
4. Sentence enhancement laws specific to STDs that do not criminalize a behavior but increase the sentence length when a person with an STD, which might include HIV, commits certain crimes.
5. No specific criminalization laws.

Objective 3.2: Reduce disparities in new HIV infections, knowledge of status, and along the HIV care continuum

Monitoring of progress toward HIV targets should identify, raise awareness of, and inform appropriately tailored interventions to respond to ongoing and emerging disparities among various populations and in geographic areas. With improved mechanisms to measure, monitor, and report data in a timely manner and enhanced quality, accessibility, sharing, and use of data (see Goal 4), governments and organizations can more quickly identify disparities and direct resources appropriately.

When disparities are identified, tailored interventions must be developed in partnership with the affected populations. Specific populations may have unique or specialized needs and face challenges that require more tailored approaches based on sociodemographic, geographic, cultural, and other characteristics that may be associated with HIV risk or health-promoting behaviors.

Strategies

- 3.2.1 Increase awareness of HIV-related disparities through data collection, analysis, and dissemination of findings.
- 3.2.2 Develop new and scale up effective, evidence-based or evidence-informed interventions to improve health outcomes among priority populations and other populations or geographic areas experiencing disparities.

Objective 3.3: Engage, employ, and provide public leadership opportunities at all levels for people with or at risk for HIV

Achieving the goals of this Plan and ending the HIV epidemic demand a whole-of-society effort that must include and elevate the diverse voices and experiences of people with or at risk for HIV, as well as their partners, families, and communities. Jurisdictions and organizations must meaningfully engage and employ people with or at risk for HIV in the development, implementation, monitoring, and assessment of policies, programs, and services. This includes creating opportunities for employment and advancement wherever possible, particularly for individuals from the priority populations identified in this Plan. Their experiences can inform efforts to remove barriers that hinder access to needed information or services and to design services that meet unique needs as well as enhance cultural competency. Governments and other institutions working to meaningfully engage people with or at risk for HIV must develop partnerships with networks of people with or at risk for HIV and other organizations that engage and serve populations most affected by HIV in each community, identifying ways to optimize messages and services and to combat stigma and discrimination.

Strategies

- 3.3.1 Create and promote public leadership opportunities for people with or at risk for HIV.
- 3.3.2 Work with communities to reframe HIV services and HIV-related messaging so they do not stigmatize people or behaviors.

Objective 3.4: Address social determinants of health and co-occurring conditions that exacerbate HIV-related disparities

Addressing social determinants of health and other co-occurring conditions, such as noncommunicable comorbidities and co-infections, is essential to reducing HIV-related health disparities and inequities. For many people with or at risk for HIV, addressing basic and immediate needs, such as safety and/or shelter, takes precedence over HIV testing, prevention, care, or treatment. Lack of continuous health insurance coverage, inability to pay for care and treatment, inadequate housing, food insecurity, under- and unemployment, medical mistrust, provider misconceptions and bias, low health literacy, language barriers, and involvement in the justice system all act as barriers to improved HIV outcomes. In other cases, people may be interested in HIV services, but shortages of a skilled and competent workforce or lack of nearby HIV services hinders their ability to access them. These limitations are made worse by inadequate infrastructure, including limited or no broadband internet services and lack of public transportation.⁸⁰

Ending the HIV epidemic requires recognition of the need for interventions and pooled resources to address upstream factors often rooted in racism and other social and structural barriers.¹¹⁶ Programs could destigmatize HIV services, increase service utilization, and improve health outcomes by integrating them in multi-disease, community-based testing, care, and treatment models.¹¹⁷ Ultimately, the success of biomedical and behavioral interventions may be directly impacted by whether structural interventions are effectively integrated to support them. Such integration supports person-centered care that considers all of the patient's needs including those that vary across the life span, not only those related to HIV (see Box 8). Integration also includes establishing additional opportunities to engage in partnerships that make it possible to address clients' unmet needs, maximize reach, and promote efficiency and sustainability.



BOX 8

ADDRESSING HIV PREVENTION AND CARE ACROSS THE LIFESPAN

Responsive services that recognize and support variable and episodic needs across the lifespan are necessary to best support people with or at risk for HIV. Although rare, perinatal transmission of HIV still occurs in the United States but disproportionately impacts Black children.¹¹⁸ Youth experience worse HIV outcomes on status awareness, PrEP uptake, and health outcomes. Children and young adults with HIV need tailored and often more intensive medical and support services to support them as they grow and become young adults. Relatedly, preventing mother-to-child transmission requires intensive case management and coordination across many systems and payors. Schools play an important role in the primary prevention of HIV in youth by offering on-site sexual health services through school-based health centers and school nurses, or in collaboration with community partners that provide services, such as periodic, school-wide HIV screening events or mobile clinics. Schools that cannot provide direct sexual health services can establish integrated referral systems that link students to youth-friendly providers in the community. There is a need for both primary prevention approaches and HIV care models that are tailored to groups of youth at disproportionate risk of HIV, including young gay, bisexual, and other men who have sex with men and people who inject drugs.

Similarly, tailored approaches are required to meet the HIV prevention, testing, and care needs of older adults. Older Americans are more likely than younger Americans to be diagnosed with HIV infection late in the course of their disease, meaning they get a late start to treatment and possibly experience more damage to their immune system. Thanks to effective HIV care and treatment, people with HIV who are diagnosed early in their infection, and who get and stay on ART, can keep the virus suppressed and live long and healthy lives. As a result, the number of older adults with HIV is growing; more than one-half of people with diagnosed HIV in the United States were aged 50 and older in 2018.¹⁰⁶ Older people with HIV, especially long-term survivors, face different health and psychosocial issues than their younger counterparts and thus require appropriately tailored HIV care and treatment services. These unique needs include screening for, assessing, and treating HIV-associated non-AIDS conditions as well as age-associated diseases for which people with HIV are at increased risk, and addressing social challenges such as social isolation or depression faced by many people aging with HIV and especially those who are long-term survivors of the disease. As this population continues to age, it will be necessary to research, develop, and implement effective interventions, and adapt and appropriately fund systems of care, with attention to comorbidities related to aging.



BOX 8, *continued*

ADDRESSING HIV PREVENTION AND CARE ACROSS THE LIFESPAN

HIV systems of care must incorporate and form partnerships with senior service providers including local Area Agencies on Aging and others to ensure that older people with HIV have access to qualified medical care, behavioral health and substance use providers experienced in elder care and HIV. Ensuring agencies focused on elder services are able to provide age friendly, affirming care to gay and bisexual individuals and those with HIV is imperative as the population in need of those services continues to grow.

Sources: Mandsager et al.¹⁰, McNeil and Rowe¹¹⁹

Strategies

- 3.4.1 Develop whole-person systems of care that address co-occurring conditions for people with or at risk for HIV.
- 3.4.2 Adopt policies that reduce cost, payment, and coverage barriers to improve the delivery and receipt of services for people with or at risk for HIV.
- 3.4.3 Improve screening and linkage to services for people with or at risk for HIV who are diagnosed with and/or are receiving services for co-occurring conditions.
- 3.4.4 Develop and implement effective, evidence-based, or evidence-informed interventions that address social and structural determinants of health among people with or at risk for HIV including lack of continuous health care coverage, HIV-related stigma and discrimination in public health and health care systems, medical mistrust, inadequate housing and transportation, food insecurity, unemployment, low health literacy, and involvement with the justice system.
- 3.4.5 Develop new and scale up effective, evidence-based or evidence-informed interventions to improve health outcomes and quality of life for people across the lifespan including youth and people over age 50 with or at risk for HIV, and long-term survivors.
- 3.4.6 Develop new and scale up effective, evidence-based or evidence-informed interventions that address intersecting factors of HIV, trauma and violence, and gender especially among cis- and transgender women and gay and bisexual men.



Goal 4: Achieve Integrated, Coordinated Efforts That Address the HIV Epidemic among All Partners and Stakeholders

THE OPPORTUNITY

Since its release in 2010, the NHAS has inspired all sectors of society—including government agencies, nongovernmental organizations, and the private sector—to better coordinate the nation’s response to the HIV epidemic. This iteration of the HIV Plan continues to recognize the importance of more integrated, coordinated efforts.

Even greater coordination is possible and is essential to ending the HIV epidemic in America. Opportunities include partnerships to meet unmet needs, maximize reach, share best practices to overcoming common

challenges, leverage available data, and promote efficiency and sustainability. Greater integration of services is crucial to meeting the nation's HIV testing, prevention, care, treatment, and supportive service needs, especially for people living in under-resourced areas and/or who are not effectively reached and engaged by existing programs and services.

It is also essential to address the syndemic of HIV, STIs, viral hepatitis, and substance use and mental health disorders. Collaborative efforts cannot be a one-way street, only benefiting the goals of HIV programs; rather, they should address how HIV programs can facilitate the attainment of other programs' goals that contribute to the overall health and well-being of the populations served.

Activities that exemplify improved integration and coordination of efforts have included the following:

- **CDC and HRSA's 2015 joint guidance to health departments and planning groups that they fund to develop a single, multi-year Integrated HIV Prevention and Care Plan.** This guidance satisfied the legislative and programmatic requirements of both agencies and served as a jurisdictional HIV/AIDS Strategy.¹²⁰ The integrated plan reduced duplicative planning and reporting efforts experienced by grantees; streamlined the work of health department staff and HIV planning groups; and promoted improved collaboration and coordination in the use of data to inform HIV prevention and care program planning, resource allocation, evaluation, and continuous quality improvement.
- **Integration of CDC funding for health department HIV surveillance and prevention.** In 2018, CDC renewed and strengthened its flagship funding program to support HIV surveillance and prevention efforts led by state, territorial, and local health departments with 5-year funding awards that integrated HIV surveillance and prevention programs for the first time. Integration helps health departments plan and execute more efficient, coordinated, and data-driven prevention efforts.
- **Pilot programs that have demonstrated the effectiveness of collaborative data-to-care (D2C) approaches.** Using HIV surveillance and other data to improve continuity of HIV care, these pilot programs integrate public health data and health care delivery to identify people with an HIV diagnosis who are not engaged in medical care or other services and facilitate linkage to care. The pilots have demonstrated effectiveness in achieving their goal of increasing the number of people with HIV who are reengaged in care and virally suppressed.¹²¹
- **Integration of data across programs to improve design and delivery of services.** HRSA and the Department of Housing and Urban Development (HUD) collaborated to better coordinate HIV care and housing services through data integration and to ultimately improve health outcomes along the HIV care continuum.¹²²



GOAL 4: ACHIEVE INTEGRATED, COORDINATED EFFORTS THAT ADDRESS THE HIV EPIDEMIC AMONG ALL PARTNERS AND STAKEHOLDERS

Objectives

- 4.1 Integrate programs to address the syndemic of HIV, sexually transmitted infections (STIs), viral hepatitis, and substance use and mental health disorders
- 4.2 Increase coordination of HIV programs across all levels of government (federal, state, tribal, local, and territorial) and with faith-based and community-based organizations, the private sector, academic partners, and the community
- 4.3 Enhance the quality, accessibility, sharing, and use of data, including HIV prevention and care continuum and social determinants of health data
- 4.4 Identify, evaluate, and scale up best practices including through translational, implementation, and communication science research
- 4.5 Improve mechanisms to measure, monitor, evaluate, report, and disseminate progress toward achieving organizational, local, and national goals

- **HRSA, NIH, and CDC Implementation Science Workgroup.** In 2018 the HRSA HIV/AIDS Bureau began a close collaboration with the CDC Division of HIV/AIDS Prevention and the National Institutes of Health's National Institute of Mental Health (NIMH) to create a platform for dialogue across federal agencies working to apply implementation science in HIV, establishing the Federal Implementation Science Workgroup. Funding opportunity announcements have been developed collaboratively, which seek to strengthen the research/service delivery collaboration between NIH investigators and implementers such as at sites funded by CDC, HRSA, the Indian Health Service (IHS), and the Substance Abuse and Mental Health Services Administration (SAMHSA), and other providers of HIV prevention and care services. Applicants develop creative, locally defined, and culturally sensitive concepts that align with the EHE jurisdictional plans.¹³⁸
- **A growing awareness of the need to better integrate services for populations vulnerable to multiple health concerns.** For example, a 2019 National Academies of Sciences, Engineering, and Medicine workshop highlighted the importance of addressing infectious diseases as part of an improved, comprehensive opioid response and noted that separately administered substance use disorder treatment and infectious disease services often inhibit comprehensive care.¹²³ In addition, in 2020 SAMHSA published [*Prevention and Treatment of HIV Among People Living with Substance Use and/or Mental Disorders*](#), a guide that addresses the co-occurrence of HIV and mental illness and/or substance use disorder and reviews effective programs and practices to prevent HIV and, for those with HIV, to increase linkage and retention in care in order to improve health outcomes.
- **Use of new HIV surveillance techniques.** CDC has supported several jurisdictions to detect possible HIV infection clusters more quickly and then coordinate swift responses across programs to get needed prevention and treatment services to people who need them. As work continues to expand the ability to identify and quickly respond to new HIV infections, health departments and communities must work together to collectively address the consent, privacy, and data use concerns.
- **Provisions in the 21st Century Cures Act on the interoperability of health information.** These provisions, including those related to social determinants of health, put the patient at the center of care and promote secure health information exchange to enable improved coordination, targeting of resources, and research that can support achieving the Plan's goals.
- **Partnerships with Medicaid programs.** Through these partnerships, several state HIV programs have been able to implement performance measures that reward providers with increased numbers of patients who have achieved and maintained viral suppression.
- **Enhanced efforts to integrate services and disciplines in health care delivery.** In recent years greater emphasis has been placed on integrating behavioral health (mental health and substance use disorder) services and primary care and vice versa. Expanding availability of medication-assisted treatment for substance use disorder in primary care settings is one example. Similarly, to serve the growing population of people with HIV over age 50, more clinics are adopting a geriatric multidisciplinary approach to health care, addressing the domains of medical problems, cognitive and functional abilities, psychiatric disorders, and social circumstances.¹²⁴

THE CHALLENGES

To realize the goal of achieving more integrated, coordinated efforts that address the HIV epidemic among all partners and stakeholders, the following challenges must be addressed:

- Rising rates of substance use, including the ongoing opioid epidemic and increasing use of methamphetamine, have resulted in concurrent infectious disease epidemics. This trend threatens to reverse substantial progress achieved in reducing new HIV transmissions among people who inject drugs and people who use substances. Better integrated responses to the syndemic of HIV, STIs, viral hepatitis, and substance use and mental health disorders are needed.

- The experience of enhanced coordination at the federal level must expand to include other relevant departments and agencies. It must also cascade to the state, tribal, and local levels and include partners such as law enforcement, health care providers, pharmacists, community health workers, aging and social services providers, schools, and public and private payers.
- Additional data integration across federal, state, tribal, and local programs is needed to better understand and influence the social determinants of health in an effort to improve the health and well-being of all communities at risk and living with HIV.
- There is a need to support jurisdictions and organizations to develop, implement, monitor, and update locally tailored plans to end the HIV epidemic that are informed by community input and that expand engagement of partners and sectors to meet the distinct needs of populations with or at risk for HIV.
- The necessary focus on COVID-19 has diverted attention and strained capacity in state and local health departments and community-based organizations.
- Fee-for-service and other payment models do not adequately support integrated, comprehensive health care delivery models, such as behavioral health and medical care integration, patient-centered medical homes, services provided by pharmacists in non-traditional roles, integration with support services, oral health care, and care coordination. Grant funding to support pilots or demonstrations of such integrated models is limited and time-bound. Scaling up and sustaining these effective care delivery models require evolutions in public and private payer systems.

SUMMARY OF OBJECTIVES

The following objectives are critical to achieving integrated, coordinated efforts that address the HIV epidemic among all partners and stakeholders:

- 4.1 Integrate programs to address the syndemic of HIV, STIs, viral hepatitis, and substance use and mental health disorders.
- 4.2 Increase coordination of HIV programs across all levels of government (federal, state, tribal, local, and territorial) and with public and private health care payers, faith-based and community-based organizations, the private sector, academic partners, and the community.
- 4.3 Enhance the quality, accessibility, sharing, and use of data, including HIV prevention and care continuum data and social determinants of health data.
- 4.4 Identify, evaluate, and scale up best practices including through translational, implementation, and communication science research
- 4.5 Improve mechanisms to measure, monitor, evaluate, and use the information to report progress and course correct as needed in order to achieve the HIV Plan goals.

OBJECTIVES AND STRATEGIES

Objective 4.1: Integrate programs to address the syndemic of HIV, STIs, viral hepatitis, and substance use and mental health disorders

The syndemic of HIV, STIs, viral hepatitis, and substance use and mental health disorders in the United States highlights overlapping risk factors as well as associations with social determinants of health such as poverty, lack of health insurance, housing instability, and other related inequities. An effective response to the syndemic requires integration of programs to enable increased flexibility in utilization of allocated resources; better coordinated policy and program planning, development, and delivery; and rapid adjustment to new data or scientific advances. For such integration to occur, major shifts in policy, systems, and societal norms and attitudes must occur, and the willingness to explore new and nontraditional approaches and strategies must increase.

A National Academies report recommends that the syndemic be addressed via integrated medical services¹²³ in place of often siloed services. Opportunities are missed every day to test people for multiple infections and to scale up services in settings where people at risk receive other services. These missed opportunities translate directly into lost time and resources and may result in harm to people who remain undiagnosed, untreated, and at risk of severe outcomes or of transmitting the infection to others. A reciprocal, integrated approach in our responses to infectious diseases, the opioid crisis, and substance use and mental health disorders that puts patients first through a status-neutral and no-wrong-door approach will maximize their ability to access services that meet their health needs. For example, HIV testing programs can identify opportunities to screen for other STIs, viral hepatitis, substance use, and intimate partner violence (IPV). Similarly, STI, substance use disorder treatment, and viral hepatitis programs can integrate HIV testing and linkage to relevant HIV prevention or care services, as appropriate.

Strategies

- 4.1.1 Expand outreach and education efforts addressing issues that intersect HIV such as intimate partner violence, STIs, viral hepatitis, and substance use and mental health disorders.
- 4.1.2 Implement a no-wrong-door approach to screening and linkage to services for HIV, STIs, viral hepatitis, and substance use and mental health disorders across programs.
- 4.1.3 Identify and address funding, policy, data, workforce capacity, and programmatic barriers to effectively address the syndemic.
- 4.1.4 Coordinate and align strategic planning efforts on HIV, STIs, viral hepatitis, substance use disorders, and mental health care across national, state, and local partners.

Objective 4.2: Increase coordination of HIV programs across all levels of government (federal, state, tribal, local, and territorial) and with public and private health care payers, faith-based and community-based organizations, the private sector, academic partners, and the community

Ending the HIV epidemic requires a whole-of-society approach. Increasing coordination across all sectors of society enables better delivery of services and resources to people with or at risk for HIV. Likewise, establishing trusted partnerships allows for coalitions to develop, implement, and regularly evaluate and update policies and programs that address the social, economic, and political environments that shape and constrain individual, community, and societal outcomes.

Increased coordination at the federal level includes expanding the partners engaged in the federal government's HIV response. Such expansion includes leveraging existing programs whose primary purpose may not be HIV services, but which could provide supportive services such as employment training or nutrition assistance to people with or at risk for HIV. Such coordination helps to ensure that resources are allocated according to current burden of disease and that the most effective prevention and care strategies are tailored to local community needs to achieve maximal results.

Better coordination at the state, tribal, local, and territorial levels involves fostering strong linkages among community-based organizations, health departments, other public programs and services, education agencies, pharmacies, health care providers and systems, and community leaders. Collaboration with community partners is particularly important to developing locally relevant plans for providing testing, prevention, care, treatment, and supportive services, including those that engage people not yet reached by existing programs and services. Such linkages support development of creative, local interventions that allow for seamless delivery of culturally relevant services to address the myriad needs of people at any number of touchpoints across the public health, health care delivery, and social services systems. Collaboration also involves engaging and building capacity and competencies among partners and communities that are interested in providing HIV services but may not have had the opportunity or resources to do so. Expanded and strengthened partnerships can better equip communities to respond swiftly and effectively to identified outbreaks of HIV, STIs, and/or viral hepatitis.

Strategies

- 4.2.1 Focus resources including evidence-based and evidence-informed interventions in the geographic areas and priority populations disproportionately affected by HIV.
- 4.2.2 Enhance collaboration among local, state, tribal, national, and federal partners and the community to address policy and structural barriers that contribute to persistent HIV-related disparities and implement policies that foster improved health outcomes.
- 4.2.3 Coordinate across partners to quickly detect and respond to HIV outbreaks.
- 4.2.4 Support collaborations between community-based organizations, public health organizations, education agencies and schools, and health care delivery systems to provide linkage to and delivery of HIV testing, prevention, care, and treatment services as well as supportive services.

Objective 4.3: Enhance the quality, accessibility, sharing, and use of data, including HIV prevention and care continuum and social determinants of health data

High-quality data are essential to the increased coordination, integration, and seamless delivery of services that are required to end the HIV epidemic. The appropriate collection and use of data can inform efforts to focus prevention and testing services on populations who need them most, can help ensure that people newly diagnosed with HIV are referred to care, and can facilitate effective treatment to help people with HIV to achieve and maintain viral suppression. However, jurisdictions need resources, guidance, and support to strengthen HIV surveillance systems and activities to obtain the data needed to improve our response to the HIV epidemic, including viral load reporting and disparities data to ensure that no populations or communities are being left behind.

Appropriate use of secure health information exchanges can help to engage and retain or reengage people in care and to facilitate transitions across care and community settings. Further, secure sharing of treatment and outcome data can drive the science needed to develop new and better treatments, approaches to retention in care, and prevention interventions. Better use of data on social determinants of health can optimize prevention efforts for at-risk groups, engage and retain people with HIV in care, support adherence to treatment, and inform ongoing research efforts to develop better treatment and prevention.

Since the last update to the HIV Plan, health information technology (health IT) has become even more widespread and interoperable, presenting numerous opportunities to enhance the availability and use of data to improve HIV prevention and treatment efforts. Successfully leveraging health IT on the ground requires additional efforts around data collection, integration, and analysis from disparate systems and standardized protocols and procedures for use and integration of health records.

Strategies

- 4.3.1 Promote the collection, efficient sharing, and use of HIV risk, prevention, and care and treatment data using interoperable data standards, including data from electronic health records.
- 4.3.2 Use interoperable health information technology, including electronic health records and health information exchange networks, to improve HIV prevention efforts and care outcomes.
- 4.3.3 Encourage and support patient access to and use of individual health information, including patient-generated health information and consumer health technology.

Objective 4.4: Identify, evaluate, and scale up best practices including through translational, implementation, and communication science research

Many significant scientific advances and best practices have been discovered during the response to the HIV epidemic. However, to achieve an impact at the population level, these discoveries must be effectively, swiftly, and broadly disseminated and brought to scale through evidence-based and culturally responsive public health and clinical practice. Conducting implementation science research, in collaboration with communities, is one

important approach to more rapidly and effectively put into practice new research findings, advances, and other tools as they become available.

Implementation science helps to identify factors that are barriers to or can help facilitate effective public health and health care services as well as informs related policy development. Knowledge of these factors can help entities successfully implement interventions with fidelity as well as support the discovery of new evidence-based practices and strategies that improve public health at all levels. For example, theoretically, the widespread provision of ART and PrEP could end the HIV pandemic. However, a gap exists between theory and reality.

Implementation gaps exist at all stages of the HIV prevention and care continuums. Progress in cities such as San Francisco and New York City, which have dramatically reduced new HIV cases by deploying ART, PrEP, and other tools, suggests that these gaps can be overcome. Such examples offer lessons for optimizing implementation research in different settings and among various populations.

In addition to supporting implementation research, there is a need to develop more opportunities and mechanisms for timely information sharing and peer technical assistance to support replication of best practices and use of lessons learned to address common barriers within and across jurisdictions.

Strategies

- 4.4.1 Promote and support collaborative research efforts among academic centers, health departments, community-based organizations, patients and their advocates, and other partners that aim to discover, adapt, and scale up effective interventions to improve HIV outcomes.
- 4.4.2 Develop opportunities and mechanisms for information sharing and peer technical assistance within and across jurisdictions.

Objective 4.5: Improve mechanisms to measure, monitor, evaluate, report, and disseminate progress toward achieving organizational, local, and national goals

There is a continued need to streamline and harmonize data reporting to reduce reporting burden and facilitate more regular, timely, and useful data. Support is also needed to adopt new analytic methods and approaches to increase the timeliness of data, enhance the ability to characterize the burden of HIV across the nation, and use that information to allocate resources to achieve the greatest impact. In addition, complementary data sources such as health care payer databases, surveys, and linkages to electronic health records are necessary to ensure robust information that can guide decision making.

Timely data will improve accountability among federally funded organizations as they set and make progress toward measurable goals and targets aligned with this Plan. Data for the indicators at the local, state, and national levels should be regularly and publicly reported and reviewed to identify successful efforts, indicate challenges, and facilitate ongoing dialogue about ways to continue moving forward. Such reporting and review require a monitoring plan that evaluates the implementation of the HIV Plan. A system of regular public reporting will help to sustain public attention and support at the national level. Organizations that struggle to engage new stakeholders or fall short of expected outcomes should receive intensive capacity-building assistance and other supportive measures as a condition of continued funding. The nation can thus direct its funds to entities and initiatives that demonstrate the highest level of performance and accountability for high-impact HIV prevention.

Strategies

- 4.5.1 Streamline and harmonize reporting and data systems to reduce burden and improve the timeliness, availability, and usefulness of data.
- 4.5.2 Monitor, review, evaluate, and regularly communicate progress on the HIV National Strategic Plan.
- 4.5.3 Ensure that HIV National Strategic Plan goals are included in cross-sector federal funding requirements.
- 4.5.4 Strengthen monitoring and accountability for adherence to requirements, targets, and goals by funded partners.
- 4.5.5 Identify and address barriers and challenges that hinder achievement of goals by funded partners and other stakeholders.

III. IMPLEMENTATION AND ACCOUNTABILITY

Federal Partners

The HIV Plan provides a framework for ending the HIV epidemic in the United States. Development of the HIV Plan was a collaborative process led by federal partners across multiple departments and agencies with input from a diverse range of stakeholders from across the nation.

Federal partners will collaborate to develop an implementation plan to pursue the HIV Plan goals, objectives, and strategies. The Federal Implementation Plan will set forth federal partners' commitments to policies, initiatives, and activities to meet the goals of the HIV Plan and will be published for transparency and accountability. The Federal Implementation Plan will also include details on the definitions, specifications, and targets for the indicators of progress.

As part of their ongoing commitment to reduce HIV in this nation, federal partners have committed to serve on an HIV Plan implementation working group. This implementation working group will collaborate on addressing HIV in an integrated fashion by including other infectious diseases as components of the syndemic. The working group will meet regularly to coordinate activities across agencies and departments, implement lessons learned from epidemiological data and research findings, monitor progress toward the indicator targets, course correct as needed, and report on national progress. As scientific, medical, and public health advances and challenges emerge, new and innovative policies will be developed to complement the existing HIV plan.

Nonfederal Partners

Addressing HIV is not solely a federal activity. Success depends on coordinated action by state, tribal, territorial, and local governments; community-based organizations and faith-based organizations; health plans and payers, health care providers, and other health-related organizations; the criminal justice system; universities, schools, and other avenues for educational activities; researchers; families; and patients and their partners. Its success also depends on a holistic approach to the various parts of the syndemic, including STIs, viral hepatitis, substance use and mental health disorders, stigma and discrimination, and social and structural determinants of health.

Each community and stakeholder brings a unique perspective and plays a critical role in preventing and responding to HIV. Over the past several years many states and localities have engaged in community-wide efforts to develop their own plans to end the HIV epidemic. Stakeholders are encouraged to use this HIV Plan to engage with others and build or update their own roadmap to reduce HIV and end the HIV epidemic among the populations and communities they serve. Stakeholders should consider adopting the vision and goals of this HIV Plan; pursuing the objectives and implementing the strategies relevant to their role(s), populations served, and community circumstances; and identifying opportunities to adopt and use the Plan's indicators and targets to measure their own progress. In doing so, communities and stakeholders can also apply other evidence-based strategies appropriate for responding to HIV in their area and use all available data to identify where their resources and effort will have the most impact. A data-driven strategy will help stakeholders focus efforts and efficiently and effectively use available resources. Integrating HIV testing, prevention, care, and treatment efforts with other components of the syndemic, including emerging issues such as the COVID-19 pandemic, is also strongly encouraged.

APPENDIX A: PROCESS/METHODOLOGY FOR DEVELOPING AND ADOPTING THE HIV PLAN

In 2018, recognizing the importance of the then current NHAS, which expired in 2020, ADM Brett Giroir, MD, Assistant Secretary for Health at HHS, outlined a process for developing the next iteration of this HIV Plan in parallel with the Viral Hepatitis National Strategic Plan, which also expired in 2020.

The Office of Infectious Disease and HIV/AIDS Policy (OIDP), within the Office of the Assistant Secretary for Health at HHS, has facilitated development of this HIV Plan. OIDP has collaborated with partners from across many federal departments and agencies to compile the best available evidence and recommendations, solicited input from various external stakeholders, including the public, and integrated these various inputs into this HIV Plan to set the country on a path toward ending the HIV epidemic.

Concurrent development of the HIV Plan and the Viral Hepatitis Plan has allowed for general alignment of their visions, goals, objectives, and strategies. These plans were developed by leveraging a common infrastructure, and they each aims to capitalize on synergistic opportunities to jointly address HIV and viral hepatitis. Nevertheless, despite this overlap, HIV and viral hepatitis each present unique public health challenges that justify releasing the two plans separately. These two plans have also been developed in partnership with development of the first-ever STI National Strategic Plan.

Federal Leadership

STEERING COMMITTEE

A joint federal Steering Committee for developing the HIV Plan and the Viral Hepatitis Plan set the vision, goals, objectives, and priority populations; discussed key challenges to be addressed in the HIV Plan; and approved the indicators to measure progress for the nation. The Steering Committee's work and decision-making were informed by presentations and discussions of national-level data; current HIV programs—especially those funded by federal departments and agencies; challenges and gaps in addressing HIV in this nation; and integration of and leveraging the work being conducted to address other components of the syndemic. The Steering Committee provided direction for the process. In addition, the Steering Committee formed subcommittees to study and propose objectives, strategies, and indicators for each of the HIV Plan's goals and, in doing so, consider information gathered during the public input period. Development of the objectives and strategies was an iterative process among the Steering Committee, the various subcommittees, and the committees developing the Viral Hepatitis Plan and the STI Plan, as well as OIDP leadership. These contributors conducted analyses to identify gaps as well as opportunities for alignment within the HIV Plan and among all of the national strategic plans. The Steering Committee voted to approve components of the HIV Plan (e.g., vision, goals, objectives, priority populations, and indicators). The Steering Committee consisted of senior representatives from six federal departments and 12 HHS agencies and offices (see Table A.1).

It met regularly from January 2019 through February 2020, and then as needed thereafter.

Table A.1. Composition of Joint Viral Hepatitis/HIV Federal Steering Committee

Federal Departments	HHS Agencies/Offices	
<ul style="list-style-type: none"> • Defense • Justice • Equal Employment Opportunity Commission • Health and Human Services • Housing and Urban Development • Veterans Affairs 	<ul style="list-style-type: none"> • Administration for Community Living • Agency for Healthcare Research and Quality • Centers for Disease Control and Prevention • Centers for Medicare & Medicaid Services • Food and Drug Administration • Health Resources and Services Administration • Indian Health Service 	<ul style="list-style-type: none"> • National Institutes of Health • Office of the Assistant Secretary for Health <ul style="list-style-type: none"> » Office of Infectious Disease and HIV/AIDS Policy » Office of the Surgeon General • Office for Civil Rights • Office of the National Coordinator for Health Information Technology • Substance Abuse and Mental Health Services Administration

SUBCOMMITTEES

The Steering Committee members formed three HIV subcommittees, one for each topic listed by the bullets below, and selected subject matter experts from each agency or office to participate:

- Prevention and Care;
- Disparities and Coordination; and
- Indicators.

These subcommittees were charged with developing and recommending objectives, strategies, and indicators. Each had at least two co-chairs and consisted of subject matter experts from across the government. Subcommittees met at least monthly to review the latest science and evidence and to develop objectives and strategies for each goal, as well as indicators, for discussion and approval by the Steering Committee. The Indicators Subcommittee also coordinated with its counterparts for the next Viral Hepatitis Plan and the inaugural STI Plan to aim for consistency of criteria and methods used across plans.

Public Input

A crucial component in developing the HIV Plan was engagement and input from nonfederal stakeholders. Stakeholders from all sectors and at all levels (i.e., community, state, regional, national) and people whose lives have been affected by HIV were encouraged to provide input on the HIV Plan.

SOLICITATION OF PUBLIC INPUT

To assist in developing the HIV Plan, public input on the Plan was solicited. Between September 2018 to March 2019, ODP conducted 18 listening sessions at national conferences, state and regional community planning meetings, prevention trainings in rural areas, federal advisory committees, and virtual meetings throughout the United States. Throughout this process, ODP received 312 listening session comments regarding the HIV Plan.

In addition, a [Request for Information](#) (RFI) was published in the *Federal Register* during February 2019, which resulted in receipt of 49 written public comments on development of the HIV Plan. After de-duplication, ODP received a total of 344 comments from unique respondents.

METHOD OF ANALYSIS

All verbal and written comments were collated by commenter and organization. A pre-determined coding structure was developed based on questions posed during the listening sessions and in the RFI. Two coders analyzed all comments and coded the comments to themes. Coders reviewed the comment data and updated the codebook based upon dominant and emergent themes present in both listening session and RFI comments. Staff performed a qualitative analysis of all comments using NVivo 12.0, examined them for dominant themes and subthemes, and matched them to HIV Plan goals.

COMMENTERS

A total of 155 commenters were able to be identified and categorized into various respondent types. Overall, there was strong representation from community-based organizations/faith-based organizations (n=34), health care providers (n=27), national organizations (n=25), state health departments (n=14), and patients (n=14) (see Figure A.1).




Figure A.1. Respondent type for all public comments with available affiliation

SUMMARY OF FINDINGS

Methods used and findings from the public input, including prominent themes and sub-themes along with supporting comments, were presented to the Steering Committee and the subcommittees. Input received through public comments was extremely valuable, and comments addressed a broad range of HIV-related topics that are reflected in the HIV Plan’s goals, objectives, and strategies; dominant themes are listed in Table A.2.

Table A.2. Dominant Themes from Public Comments

Theme	Number of Comments (%) N=344
Priority Populations	156 (45.36%)
Coordination	113 (32.8%)
Social Determinants of Health	110 (32.0%)
Prevention	92 (26.7%)
Health Care Financing	77 (22.4%)
Funding	67 (19.5%)
Care	63 (18.3%)
Substance Use	41 (11.9%)
STIs	38 (11.0%)
Screening and Diagnostics	27 (7.8%)
Research	17 (4.9%)
Viral Hepatitis	16 (4.7%)

Many comments pertained to the work or purview of specific agencies. These agency-specific comments were also compiled into individual reports and shared with those agencies for review and consideration.

PUBLIC COMMENT ON THE DRAFT HIV PLAN

In December 2020, ODP published an [RFI](#) in the *Federal Register* inviting public comment on the draft HIV National Strategic Plan. Sixty commentors shared more than 370 comments on the draft plan, which were reviewed and considered as final edits were made to the Plan. The commentors represented a wide variety of stakeholders including individuals with or at risk for HIV, groups representing people with HIV, state and local health departments, health care providers, researchers, housing services advocates, and others.

Identification of Priority Populations Based on National-Level Data

The Indicators Subcommittee was tasked with identifying priority populations for the HIV Plan. Priority populations are disproportionately affected populations, which are defined as groups of people with a higher burden of disease than others. HIV testing, prevention, care, and treatment interventions and resources can be delivered to priority populations for the greatest impact. With the understanding that the HIV Plan is a national plan, the Steering Committee reviewed national HIV surveillance data to select priority populations.

As a starting point, CDC's Division of HIV/AIDS Prevention presented HIV surveillance data. The data considered included (1) incidence of new HIV infections including trends, (2) prevalence of HIV, (3) diagnoses, (4) results across major HIV outcomes, and (5) potential impact of other major public health threats (e.g., opioid epidemic, STDs). The subcommittee reviewed and discussed the data over several meetings and voted to recommend to the Steering Committee priority populations based on the available surveillance data.

Examination of the 2018 national-level data illustrated the disparate impact of HIV on the five groups designated as priority populations in the HIV Plan (see Table A.3):

- gay, bisexual, and other men who have sex with men (MSM), in particular Black, Latino, and American Indian/Alaska Native men;
- Black women;
- transgender women;
- youth aged 13–24 years; and
- people who inject drugs.

Table A.3. Priority Populations and Summary National-Level Data, Calendar Year 2018 (unless otherwise indicated)

Gay, Bisexual, and Other MSM

- Gay, bisexual, and other men who have sex with men are the population most affected by HIV in the United States. At the end of 2018, an estimated 1,173,000 people had HIV in the United States. Of those, 740,400 (63.1%) were gay and bisexual men.^{2,125}
- In 2018, adult and adolescent gay and bisexual men represented 67% (24,400) of the 36,400 new HIV infections in the United States.²
- The incidence of many STDs in gay, bisexual, and other men who have sex with men—including primary and secondary syphilis and antimicrobial-resistant gonorrhea—is greater than that reported in women and men who have sex with women only.⁴³ Having another STD can greatly increase the chance of getting or transmitting HIV. Ten percent of new HIV infections among MSM are estimated to be attributable to gonorrhea and chlamydia, equating to 2,600 HIV infections each year.⁴⁵

Black MSM

- Black gay, bisexual, and other MSM are more affected by HIV than any other group in the United States.
- In 2018, Black gay and bisexual men accounted for 26% (9,400) of the 36,400 new HIV infections and 39% of the 24,400 new infections among all gay and bisexual men in the United States.²
- Of the 37,968 new HIV diagnoses in the United States and dependent areas in 2018, 26% were among Black gay and bisexual men.
- Along the HIV care continuum, compared to all people with diagnosed HIV in 41 states and the District of Columbia, Black gay and bisexual men have lower viral suppression rates.⁷ (See Figure A.2.)

Latino MSM

- Latino gay, bisexual, and other MSM are heavily affected by HIV. In 2018, adult and adolescent Latino gay and bisexual men comprised 22% (8,000) of the 36,400 new HIV infections in the United States and 33% among all gay and bisexual men in the United States.²
- Of the 37,968 new HIV diagnoses in the United States and dependent areas in 2018, 21% were among Latino gay and bisexual men.¹⁰⁶

American Indian/Alaska Native MSM

- American Indian/Alaska Native MSM are disproportionately affected by HIV. In 2018, 75% (140/186) of diagnoses occurring among American Indian/Alaska Native people were among MSM.¹⁰⁶
- HIV diagnoses among American Indian/Alaska Native gay and bisexual men increased 15% between 2014–2018, while diagnoses among gay and bisexual men of other races/ethnicities were either stable or declined.¹⁰⁶

Black Women

- Although data show a 22% decrease in new HIV infections among Black women between 2010 and 2018, among all women in the United States, Black women accounted for the largest share of 6,700 new HIV infections (3,800 or 57%) in 2018).^{2,8}
- The rate of new HIV infections among Black women (21.3 per 100,000) is nearly 13 times as high as the rate among white women (1.7 per 100,000) and more than 4 times as high as the rate among Latinas (5.0 per 100,000).²

Transgender Women

- A 2019 systematic review and meta-analysis found that an estimated 14% of transgender women have HIV.¹⁴
- By race/ethnicity, an estimated 44% of Black transgender women, 26% of Latina transgender women, and 7% of white transgender women have HIV.¹⁴
- Among the 3 million HIV testing events reported to CDC in 2017, the percentage of transgender people who received a new HIV diagnosis was three times the national average.¹²⁶

Youth Aged 13–24 Years

- In 2018, youth aged 13–24 accounted for 21% (7,891) of the 37,968 new HIV diagnoses in the United States and dependent areas. Most new HIV diagnoses among youth were among young gay and bisexual men.¹⁰⁶
- Only 9% of high school students have been tested for HIV and therefore do not know their HIV status. Among male students who had sexual contact with other males, only 15% have ever been tested for HIV.¹²⁷
- In 2018, youth with diagnosed HIV were also the least likely of any age group to be linked to care within 1 month of diagnosis (77.2%).¹²⁸ Further, compared to all people with HIV, youth have the lowest rates of viral suppression. For every 100 youth with HIV, 43 received some HIV care, 32 were retained in care, and 33 were virally suppressed.¹²⁸
- People aged 15–24 account for approximately 50% of the 20 million new STIs in the United States each year, yet approximately 25% of the sexually active population.⁴³ Having another STI can greatly increase the chance of getting or transmitting HIV.

People Who Inject Drugs

- People who inject drugs are at high risk for getting HIV if they use and share needles, syringes, or other drug injection equipment that someone with HIV has used.
- New HIV diagnoses among people who inject drugs have increased 8.6% in recent years (from 2,294 diagnoses in 2014 to 2,492 diagnoses in 2018) in the United States and dependent areas.¹⁰⁶
- Although HIV incidence among people who inject drugs has declined substantially over many years, the ongoing misuse of opioids and other frequently injected substances are threatening this HIV prevention success. HIV diagnoses among people who inject drugs increased by 11% nationally from 2016 to 2018, with more pronounced increases among adults younger than age 40 and non-Hispanic white adults.¹⁰⁶ Multiple recent clusters and outbreaks have contributed to new HIV infections among people who inject drugs.¹²⁹
- Among people with HIV who inject drugs, 62–81% were co-infected with hepatitis C.¹⁸ People with HIV co-infected with hepatitis B or hepatitis C have higher liver-related morbidity and mortality, and higher overall mortality than patients only infected with hepatitis B or hepatitis C.^{130,131,132}

Figure A.2 depicts the subpopulations with the most new HIV diagnoses in 2018.




Figure A.2. New HIV diagnoses in the United States and dependent areas for the most-affected subpopulations, 2018

Notes: Black refers to people having origins in any of the Black racial groups of Africa. African American is a term often used for Americans of African descent with ancestry in North America. Hispanics/Latinos can be of any race. Subpopulations representing 2.0% or less of all people who received an HIV diagnosis in 2018 are not represented in this chart. Source: Centers for Disease Control and Prevention.¹³³

Figures A.3 and A.4 depict the disparities along the HIV care continuum experienced by Black gay, bisexual, and other men who have sex with men and youth aged 13–24.




Figure A.3. Disparities along the HIV care continuum among Black gay, bisexual, and other men who have sex with men, 2018

Notes: Black refers to people having origins in any of the Black racial groups of Africa. African American is a term often used for Americans of African descent with ancestry in North America. Includes infections attributed to male-to-male sexual contact only. Among Black/African American men with HIV infection attributed to male-to-male sexual contact and injection drug use, 94% knew they had HIV. Source: Centers for Disease Control and Prevention.¹³⁴

Compared to all people with HIV, youth have the lowest rates of viral suppression.
For every 100 youth with HIV:




Figure A.4. Disparities along the HIV care continuum among youth, aged 13–24 years, 2018. Source: Centers for Disease Control and Prevention.¹⁶

The Indicators Subcommittee was selective in the total number of priority populations so that limited resources and interventions can focus on a smaller number of populations to have the greatest impact on outcomes for the nation. It was also recognized that certain settings, such as jails and prisons, and geographical areas, including the South and some urban and rural areas, have populations disproportionately affected by HIV.

The HIV Plan recognizes the importance of providing HIV services to all populations with or at risk for HIV. Therefore, even though they were not designated as priority populations, the HIV Plan discusses the importance of addressing the unique needs of other groups, such as long-term survivors and older people with HIV or people experiencing unstable housing or homelessness.

THE NEED TO ADDRESS SOCIAL DETERMINANTS OF HEALTH AND PRIORITY POPULATIONS

Many populations disproportionately impacted by HIV have historically faced disparities in health status related to the social determinants of health, such as low-paying or inconsistent employment, unstable housing or homelessness, involvement in the criminal justice system, race/ethnicity, geographic location, or other characteristics historically linked to discrimination, stigma, or exclusion. Negative interactions with the health care or social services systems may decrease a person's likelihood of care-seeking behavior, making HIV testing, prevention, linkage to care, and adherence to treatment more difficult. This poses additional and unique challenges to the development of broad-based solutions. Focused efforts on social determinants of health are thus important to reduce the number of infections, morbidity, and mortality in these priority groups and to minimize disparities across the overall population.

PRIORITY POPULATIONS MAY DIFFER BY STAKEHOLDER

The HIV Plan also highlights selected priority populations to illustrate how data may be used to help partners with limited resources to focus their efforts for the greatest public health impact. The Plan's priority populations should be useful for federal and nonfederal partners whose purview reaches everyone in this nation. However, the groups most impacted by HIV may differ by jurisdiction or setting and may include additional or different populations or communities. Therefore, state, tribal, territorial, and local jurisdictions, as well as health care providers, health plans, community-based and faith-based organizations, advocacy groups, and other institutions should review data that pertain to the populations and communities they serve. This review will help each stakeholder determine how best to focus efforts and resources to achieve results with the highest impact.

Indicators of Progress

The Steering Committee established an Indicators Subcommittee composed of federal agency representatives. The subcommittee was tasked with developing recommendations for a small set of core indicators to measure progress toward achieving HIV Plan goals. The subcommittee incorporated as core indicators the six indicators already being used to monitor the EHE initiative and identified two other core indicators relevant to the broader scope of the HIV Plan. The subcommittee also identified a core indicator that should be stratified by the HIV Plan's priority population to serve as disparities indicators. Additional information about the methodology used, indicator specifications, and indicator targets will be provided as part of the Federal Implementation Plan.

APPENDIX B: FEDERAL STEERING COMMITTEE, SUBCOMMITTEES, AND STAFF

Federal Steering Committee Members

As of September 2020

Chair

Carol Jimenez, JD
Deputy Director for Strategic Initiatives
Office of Infectious Disease and HIV/AIDS Policy (OIDP)
Office of the Assistant Secretary for Health (OASH)

HIV Plan Lead

Harold J. Phillips, MRP
Senior HIV Advisor and Chief Operating Officer, *Ending the HIV Epidemic* Initiative
OIDP/OASH

OIDP Subject Matter Lead

Nate Fecik, MPH
Public Health Analyst
OIDP/OASH

DEPARTMENT OF DEFENSE (DoD)

CDR Todd Gleeson, MD
Officer-in-charge, Navy Bloodborne Infection Management Center, U.S. Navy

Donald Shell, MD, MA
Director, Disease Prevention, Disease Management and Population Health Policy & Oversight
Office of the Assistant Secretary of Defense for Health Affairs

DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS)

Administration for Community Living (ACL)

Vicki Gottlich, JD, LLM
Director, Center for Policy and Evaluation

Agency for Healthcare Research and Quality (AHRQ)

Iris Mabry-Hernandez, MD, MPH
Medical Officer, Center for Evidence and Practice Improvement (CEPI), United States Preventive Services Task Force (USPSTF) Program

Howard Tracer, MD
Medical Officer, CEPI, USPSTF Program

Centers for Disease Control and Prevention (CDC)

Gail Bolan, MD
Director, Division of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)

Kathleen Ethier, PhD
Director, Division of Adolescent and School Health, NCHHSTP

Eugene McCray, MD
Director, Division of HIV/AIDS Prevention, NCHHSTP (RET)

RADM Jonathan Mermin, MD, MPH
Director, NCHHSTP

Carolyn Wester, MD, MPH
Director, Division of Viral Hepatitis, NCHHSTP

Centers for Medicare & Medicare Services (CMS)

Jeffrey Kelman, MD, MMSc
Chief Medical Officer, Center for Medicare

Shari Ling, MD
Deputy Chief Medical Officer, Center for Clinical Standards and Quality

Douglas Olson, MD, FACP (beginning August 2020)
Chief Medical Officer
Center for Medicaid and CHIP Services (CMCS)

Alice Thompson, PhD, MA
Deputy Division Director, Center for Medicare and Medicaid Innovation (CMMI)

Ellen Marie Whelan, PhD, NP, RN
Chief Population Health Officer, Center for Medicaid and CHIP Services
Senior Advisor, CMMI

Food and Drug Administration (FDA)

Poonam Mishra, MD, MPH
Deputy Division Director of Safety, Division of Antiviral Products
Center for Drug Evaluation and Research

Health Resources and Services Administration (HRSA)

Laura Cheever, MD, ScM
Associate Administrator, HIV/AIDS Bureau (HAB)

Heather Hauck, MSW, LICSW
Deputy Associate Administrator, HAB

Indian Health Service (IHS)

Rick Haverkate, MPH
Program Director, National HIV/AIDS Program

National Institutes of Health (NIH)

Carl Dieffenbach, PhD
Director, Division of AIDS
National Institute of Allergy and Infectious Diseases

Maureen Goodenow, PhD
Associate Director for AIDS Research and Director
Office of AIDS Research

Jay Hoofnagle, MD
Program Director, Division of Digestive Diseases and Nutrition
National Institute of Diabetes and Digestive and Kidney Diseases

Office for Civil Rights

Kenneth D. Johnson, JD
Section Chief, Civil Rights Division, Office for Civil Rights (OCR)

Office of the Assistant Secretary for Health

RET RADM Sylvia Trent Adams, PHD, RN, FAAN
Principal Deputy Assistant Secretary for Health and Acting Director, ODP/OASH

Janet Wright, MD, FACC
Acting Director of Science Policy
Office of the Surgeon General

Office of the National Coordinator for Health Information Technology (ONC)

Michael Wittie, MPH
Public Health Analyst, Office of Policy

Substance Abuse and Mental Health Services Administration (SAMHSA)

Neeraj Gandotra, MD
Chief Medical Officer

Kirk James, MD
Medical Officer, Center for Substance Abuse and Treatment (CSAT)

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT (HUD)

Rita Harcrow
Director, Office of Community Planning and Development (CPD)
Office of HIV/AIDS Housing (OHH)

Amy Palilonis, MSW
Senior Program Specialist, CPD, OHH

DEPARTMENT OF JUSTICE (DOJ)

CDR Katrina Klang, PharmD, NCPS
Hepatitis C Clinical Consultant Pharmacist, Bureau of Prisons

David Knight, JD
Trial Attorney, Civil Rights Division, Disability Rights Section

CAPT Tami Rodriguez, PharmD, BCPS
National HIV Pharmacist Clinical Consultant Coordinator, Bureau of Prisons

Megan Schuller, JD
Trial Attorney, Civil Rights Division, Disability Rights Section

DEPARTMENT OF VETERANS AFFAIRS (VA)

Maggie Chartier, PsyD, MPH
Deputy Director, HIV, Hepatitis, and Related Conditions Programs

Lorenzo McFarland, DHA, MPH, MSW, PMP
Senior Public Health Program Manager, HIV, Hepatitis, and Related Conditions Programs

EQUAL EMPLOYMENT OPPORTUNITY COMMISSION

Jeanne Goldberg, JD
Senior Attorney Advisor, Office of Legal Counsel

Carol Miaskoff, JD
Associate Legal Counsel, Office of Legal Counsel

Subcommittees

PREVENTION AND CARE

Co-Chairs

Antigone Dempsey, MEd, HRSA
John Weiser, MD, MPH, CDC

Fred Bamfo (SAMHSA)
Candice Beaubien (NIH)
Anthony Bethea (SAMHSA)
Ed Craft (SAMHSA)
Kevin Delaney (CDC)
Judith Ellis (SAMHSA)
Rita Harcrow (HUD)
Neeraj Gandotra (SAMHSA)
Chris Gordon (NIH)

Heather Hauck (HRSA)
Rick Haverkate (IHS)
Kirk Henny (CDC)
Jonathan Iralu (IHS)
Rebecca Levine (HRSA)
Ann Namkung (NIH)
Robyn Neblett-Fanfair (CDC)
Amy Palilonis (HUD)
Wilma Pinnock (SAMHSA)

David Purcell (CDC)
Charles Reynolds (SAMHSA)
Marcy Ronyak (IHS)
Tami Rodriguez (DOJ)
Adam Sherwat (FDA)
Judith Steinberg (HRSA)
Howard Tracer (AHRQ)
Puja Van Epps (VA)
Steven Young (HRSA)

DISPARITIES AND COORDINATION

Co-Chairs

Donna McCree, PHD, MPH, CDC
Mahyar Mofidi, DMD, PHD, HRSA

Pamela Belperio (VA)
Mitchell Berger (SAMHSA)
Janet Cleveland (CDC)
Neeraj Gandotra (SAMHSA)
Timothy Harrison (OIDP)
Rick Haverkate (IHS)

Ken Johnson (OCR)
Kimberly Konkel (SAMHSA)
Jordan Luke (CMS)
Jamie Morano (VA)
Amy Palilonis (HUD)
Susan Robilotto (HRSA)

Tami Rodriguez (DOJ)
Ivette Ruiz (SAMHSA)
Yamir Salabarría-Pena (CDC)
Megan Schuller (DOJ)
Michael Wittie (ONC)

INDICATORS

Co-Chairs

Nate Fecik, MPH, ODP
Norma Harris, MSPH, PHD, CDC

Benjamin Ayers (HUD)
Maggie Chartier (VA)
Stacy Cohen (HRSA)
Carl Dieffenbach (NIH)
Miranda Fanning (HRSA)

Irene Hall (CDC)
Hank Hoang (HRSA)
Laura Jacobus-Kantor (SAMHSA)
Kirk James (SAMHSA)
Anna Satcher Johnson (CDC)

Tracy Matthews (HRSA)
Amy Palilonis (HUD)
Rosemary Payne (SAMHSA)
Maria Rodriguez-Barradas (VA)
Mike Underwood (CDC)

Subject Matter Experts

Linda Beer (CDC)
Jennifer Fagan (CDC)

OIDP Staff Who Contributed to the HIV Plan

RET RADM Sylvia Trent Adams, PHD, RN, FAAN
Tammy Beckham, DVM, PHD
Corinna Dan, MPH, RN
Jessica Deerin, MPH
Emily Downes, MPH
Nate Fecik, MPH
Timothy Harrison, PHD
Kaye Hayes, MPA
Carol Jimenez, JD
Chinedu Okeke, MD, MPH
Harold Phillips, MRP
Judith Steinberg, MD, MPH

OIDP Contractors

Steve Holman
Ann Lefert

Rose Li & Associates under contract HHS75P00119C00076 and contract HHS75N98020R0026, in particular Nancy Tuvevson, and Blue Door Consulting.

APPENDIX C: ACRONYMS

ACL	Administration for Community Living (HHS)
AHRQ	Agency for Healthcare Research and Quality (HHS)
AIDS	acquired immune deficiency syndrome
ART	antiretroviral therapy
CDC	Centers for Disease Control and Prevention (HHS)
CEPI	Center for Evidence and Practice Improvement (AHRQ)
CMMI	Center for Medicare and Medicaid Innovation (CMS)
CMS	Centers for Medicare & Medicare Services (HHS)
COVID-19	coronavirus disease 2019
CPD	Office of Community Planning and Development (HUD)
CSAT	Center for Substance Abuse Treatment (SAMHSA)
DASH	Division of Adolescent and School Health (CDC)
DHAP	Division of HIV/AIDS Prevention (CDC)
DoD	U.S. Department of Defense
DOJ	U.S. Department of Justice
EHE	Ending the HIV Epidemic: A Plan for America
FDA	Food and Drug Administration (HHS)
HAB	HIV/AIDS Bureau (HRSA)
HHS	U.S. Department of Health and Human Services
HIV	human immunodeficiency virus
HOPWA	Housing Opportunities for Persons With AIDS
HRSA	Health Resources and Services Administration (HHS)
HUD	U.S. Department of Housing and Urban Development
IHS	Indian Health Service (HHS)
IPV	intimate partner violence
MSM	men who have sex with men
NHAS	National HIV/AIDS Strategy
NIAID	National Institute of Allergy and Infectious Diseases (NIH)
NIH	National Institutes of Health

OASH	Office of the Assistant Secretary for Health (HHS)
OCR	Office for Civil Rights (HHS)
OHH	Office of HIV/AIDS Housing (HUD)
OIDP	Office of Infectious Disease and HIV/AIDS Policy (HHS)
OSG	Office of the Surgeon General (HHS)
PEP	post-exposure prophylaxis
PrEP	pre-exposure prophylaxis
RWHAP	Ryan White HIV/AIDS Program (HRSA)
SAMHSA	Substance Abuse and Mental Health Services Administration (HHS)
SARS-CoV-2	severe acute respiratory syndrome coronavirus 2
SSP	syringe services program
STD	sexually transmitted disease
STI	sexually transmitted infection
U=U	Undetectable = Untransmittable
USPSTF	U.S. Preventative Services Task Force
VA	U.S. Department of Veterans Affairs

APPENDIX D: REFERENCES

- ¹ [National HIV Testing Day—June 27, 2019](#). *Morb Mortal Wkly Rep*. 2019;68:561. doi:<http://dx.doi.org/10.15585/mmwr.mm6825a1>
- ² Centers for Disease Control and Prevention. [Estimated HIV incidence and prevalence in the United States, 2014–2018](#). *HIV Surveillance Supplemental Report* 2020;25(1). Accessed September 28, 2020. <https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-supplemental-report-vol-25-1.pdf>
- ³ Harris NS, Johnson AS, Huang YLA, et al. [Vital Signs: status of human immunodeficiency virus testing, viral suppression, and HIV preexposure prophylaxis—United States, 2013–2018](#). *Morb Mortal Wkly Rep*. 2019;68:1117–1123. doi:<http://dx.doi.org/10.15585/mmwr.mm6848e1>
- ⁴ Li Z, Purcell DW, Sansom SL, et al. [Vital Signs: HIV transmission along the continuum of care—United States, 2016](#). *Morb Mortal Wkly Rep*. 2019;68:267–272. Figure 1. doi:<http://dx.doi.org/10.15585/mmwr.mm6811e1>
- ⁵ Centers for Disease Control and Prevention. [HIV Surveillance Data Tables](#) (early release): Core indicators for monitoring the Ending the HIV Epidemic initiative (preliminary data): HIV diagnoses and linkage to HIV medical care, 2019 (reported through December 2019); and preexposure prophylaxis (PrEP)—2018, updated. *HIV Surveillance Data Tables* 2020;1(2). Accessed October 16, 2020. <https://www.cdc.gov/hiv/library/reports/surveillance-data-tables/index.html>
- ⁶ [Vital Signs: HIV Prevention Through Care and Treatment—United States](#). *Morb Mortal Wkly Rep*. 2011(December 2);60(47):1618–1623. Accessed October 16, 2020. <https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6047a4.htm>
- ⁷ Centers for Disease Control and Prevention. [Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2018](#). *HIV Surveillance Supplemental Report* 2020;25(2). Accessed September 28, 2020. <https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-supplemental-report-vol-25-2.pdf>
- ⁸ [NCHHSTP AtlasPlus: HIV, hepatitis, STD, TB, social determinants of health data](#). Centers for Disease Control and Prevention. Accessed November 8, 2020. <https://www.cdc.gov/nchhstp/atlas/index.htm>
- ⁹ [Ryan White HIV/AIDS Program annual client-level data report 2019](#). Health Resources and Services Administration. Accessed December 11, 2020. <https://hab.hrsa.gov/sites/default/files/hab/data/datareports/RWHAP-annual-client-level-data-report-2019.pdf>
- ¹⁰ Mandsager P, Marier A, Cohen S. [Reducing HIV-related health disparities in the Health Resources and Services Administration’s Ryan White HIV/AIDS Program](#). *Am J Public Health*. 2018;108(S4):S246–S250. doi:10.2105/AJPH.2018.304689
- ¹¹ Dawson L, Kates J. [Insurance coverage and viral suppression among people with HIV, 2018](#). Kaiser Family Foundation; September 24, 2020. Accessed October 16, 2020. <https://www.kff.org/hiv/aids/issue-brief/insurance-coverage-and-viral-suppression-among-people-with-hiv-2018/>
- ¹² Hall IH, Song R, Rhodes P, et al. [Estimation of HIV incidence in the United States](#). *JAMA* 2008;300(5):520–529. doi:10.1001/jama.300.5.520

- 13 U.S. Census Bureau. [Quick Facts—United States](https://www.census.gov/quickfacts/fact/table/US/PST045219#PST045219). Accessed May 1, 2020. <https://www.census.gov/quickfacts/fact/table/US/PST045219#PST045219>
- 14 Becasen JS, Denard CL, Mullins MM, et al. [Estimating the prevalence of HIV and sexual behaviors among the US transgender population: A systematic review and meta-analysis, 2006-2017](#). *Am J Public Health*. 2019 Jan;109(1):e1-e8. doi:10.2105/AJPH.2018.304727.
- 15 U.S. Census Bureau. [Annual Estimates of the Resident Population: April 1, 2010 to July 1, 2018](https://www2.census.gov/programs-surveys/popest/tables/2010-2018/state/totals/PEPANNRES.pdf). Accessed August 2, 2019. <https://www2.census.gov/programs-surveys/popest/tables/2010-2018/state/totals/PEPANNRES.pdf>
- 16 [HIV and youth](https://www.cdc.gov/hiv/group/age/youth/index.html). Centers for Disease Control and Prevention. Accessed December 18, 2020. <https://www.cdc.gov/hiv/group/age/youth/index.html>
- 17 Yehia BR, Herati RS, Fleishman JA, et al. [Hepatitis C virus testing in adults living with HIV: a need for improved screening efforts](#). *PLoS ONE*. 2014;9(7):e102766. <https://doi.org/10.1371/journal.pone.0102766>
- 18 Spradling PR, Richardson JT, Buchacz K. [Trends in hepatitis C virus infection among patients in the HIV Outpatient Study, 1996–2007](#). *J Acquir Immune Defic Syndr*. 2010;53:388-396. doi:10.1097/QAI.0b013e3181b67527
- 19 [People Coinfected with HIV and Viral Hepatitis](https://www.cdc.gov/hepatitis/populations/hiv.htm). Centers for Disease Control and Prevention. Accessed December 18, 2020. <https://www.cdc.gov/hepatitis/populations/hiv.htm>
- 20 Centers for Disease Control and Prevention. Custom data analysis.
- 21 Antiretroviral Therapy Cohort Collaboration. [Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies](#). *Lancet HIV*. 2017;4(8):e349-e356. Accessed October 16, 2020. doi:[https://doi.org/10.1016/S2352-3018\(17\)30066-8](https://doi.org/10.1016/S2352-3018(17)30066-8)
- 22 Bavinton B, Grinsztejn B, Phanuphak N, et al. HIV treatment prevents HIV transmission in male serodiscordant couples in Australia, Thailand and Brazil. Presented at: 9th IAS Conference on HIV Science (IAS 2017); July 25, 2017; Paris, France.
- 23 Cohen MS, Chen YQ, McCauley M, et al. [Prevention of HIV-1 infection with early antiretroviral therapy](#). *N Engl J Med*. 2011;365:493-505. doi:10.1056/NEJMoa1105243
- 24 Cohen MS, Chen YQ, McCauley M, et al. [Antiretroviral therapy for the prevention of HIV-1 transmission](#). *N Engl J Med*. 2016;375:830-839. doi:10.1056/NEJMoa1600693
- 25 Rodger AJ, Cambiano V, Bruun T, et al. [Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy](#). *JAMA*. 2016;316(2):171-181. doi:10.1001/jama.2016.5148
- 26 Eisinger RW, Folkers GK, Fauci AS. [Ending the Human Immunodeficiency Virus pandemic: Optimizing the prevention and treatment toolkits](#). *Clin Infect Dis*. 2019;69(12):2212-2217. doi:<https://doi.org/10.1093/cid/ciz998>
- 27 Centers for Disease Control and Prevention. [Vital Signs](https://www.cdc.gov/nchhstp/newsroom/images/2019/hiv/hiv-transmissions-in-2016_highres.png). Accessed October 16, 2020. https://www.cdc.gov/nchhstp/newsroom/images/2019/hiv/hiv-transmissions-in-2016_highres.png

- 28 Rolle CP, Onwubiko U, Jo J, et al. [PrEP implementation and persistence in a county health department setting in Atlanta, GA](#). *AIDS Behav*. 2019 Oct;23(Suppl 3):296-303. doi:10.1007/s10461-019-02654-x.
- 29 Dodge B, Ford JV, Bo N, et al. [HIV risk and prevention outcomes in a probability-based sample of gay and bisexual men in the United States](#). *J Acquir Immune Defic Syndr*. 2019;82(4):355-361. doi:10.1097/QAI.0000000000002151
- 30 Operario D, Gamarel KE, Grin BM, et al. [Sexual minority health disparities in adult men and women in the United States: National Health and Nutrition Examination Survey, 2001–2010](#). *AM J Public Health*. 205;105(1):e27-e34. doi:10.2105/AJPH.2015.302762
- 31 Buchmueller T, Carpenter CS. [Disparities in health insurance coverage, access, and outcomes for individuals in same-sex versus different-sex relationships, 2000-2007](#). *Am J Public Health*. 2010;100(3):489-495. doi:10.2105/AJPH.2009.160804
- 32 [Trans 101: Transgender people in everyday work and life](#). UCSF Prevention Science. Accessed October 29, 2020. <https://prevention.ucsf.edu/transhealth/education/trans101#Who-Are-Transgender-People>
- 33 [Lesbian, gay, bisexual, and transgender health](#). HealthyPeople.gov. Accessed October 29, 2020. <https://www.healthypeople.gov/2020/topics-objectives/topic/lesbian-gay-bisexual-and-transgender-health?topicid=25>
- 34 National Institutes of Health. [Strategic Plan to Advance Research on the Health and Well-Being of Sexual & Gender Minorities: Fiscal Years 2021-2025](#). Accessed October 29, 2020. https://dpcpsi.nih.gov/sites/default/files/SGMStrategicPlan_2021_2025.pdf
- 35 [How COVID-19 impacts sexual and gender minorities](#). American Psychological Association. Accessed September 11, 2020. <https://www.apa.org/topics/covid-19/sexual-gender-minorities>
- 36 [Lesbian, gay, bisexual and transgender](#). Health Resources & Services Administration. Accessed October 29, 2020. <https://www.hrsa.gov/about/organization/bureaus/ohe/populations/diverse-populations.html#lgbt>
- 37 Cicero EC, Reisner SL, Silva SG, et al. [Health care experiences of transgender adults: an integrated mixed research literature review](#). *ANS Adv Nurs Sci*. 2019;42(2):123-138. doi:10.1097/ANS.0000000000000256
- 38 National Center for Transgender Equality. [The Report of the U.S. Transgender Survey; 2015](#). Accessed November 8, 2020. <https://www.transequality.org/sites/default/files/docs/USTS-Full-Report-FINAL.PDF>
- 39 National Academies of Sciences, Engineering, and Medicine. [Integrating Responses at the Intersection of Opioid Use Disorder and Infectious Disease Epidemics: Proceedings of a Workshop](#). The National Academies Press, 2018. doi: <https://doi.org/10.17226/25153>
- 40 Van Handel MM, Rose CE, Hallisey EJ, et al. [County-level vulnerability assessment for rapid dissemination of HIV or HCV infections among persons who inject drugs, United States](#). *J Acquir Immune Defic Syndr*. 2016;73(3):323-331. doi:10.1097/QAI.0000000000001098
- 41 Grov C, Westmoreland D, Morrison C, et al. [The crisis we are not talking about: One-in-three annual HIV seroconversions among sexual and gender minorities were persistent methamphetamine users](#). *J. Acquir Immune Defic Syndr*. 2020;89(3):272-279. doi:10.1097/QAI.0000000000002461
- 42 Bibliography. [HIV and Substance Use in the United States](#). Centers for Disease Control and Prevention. Accessed September 28, 2020. <https://www.cdc.gov/hiv/risk/substanceuse.html>

- 43 Centers for Disease Control and Prevention. [Sexually Transmitted Disease Surveillance 2018](#). U.S. Department of Health and Human Services; 2019. Accessed June 22, 2020. <https://www.cdc.gov/std/stats18/STDSurveillance2018-full-report.pdf>
- 44 Eisenger RW, Erbelding E, Fauci AS. [Refocusing research on sexually transmitted infections](#). *J Infect Dis*. 2020;222(9):1432–1434. doi:10.1093/infdis/jiz442
- 45 Jones J, Weiss K, Mermin J, et al. [Proportion of incident human immunodeficiency virus cases among men who have sex with men attributable to gonorrhea and chlamydia: a modeling analysis](#). *Sex Transm Dis*. 2019;46(6):357-363. doi:10.1097/OLQ.0000000000000980
- 46 Smith DK, Sullivan PS, Cadwell B, et al. [Evidence of an association of increases in pre-exposure prophylaxis coverage with decreases in human immunodeficiency virus diagnosis rates in the United States, 2012-2016](#). *Clin Infect Dis*. 2020:ciz1229. doi:10.1093/cid/ciz1229
- 47 Quinn KG, Christenson E, Sawkin MT, et al. [The unanticipated benefits of PrEP for young black gay, bisexual, and other men who have sex with men](#). *AIDS Behav*. 2020;24(5):1376-1388. doi:10.1007/s10461-019-02747-7
- 48 [What can decrease HIV risk?](#) Centers for Disease Control and Prevention HIV Risk Reduction Tool. Accessed November 23, 2020. <https://hivrisk.cdc.gov/can-decrease-hiv-risk/>
- 49 Marks G, Crepaz N, Janssen, RS. [Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA](#). *AIDS*. 2006; 20(10):1447-1450. doi:10.1097/01.aids.0000233579.79714.8d 0
- 50 U.S. Preventive Services Task Force. [Final Recommendation Statement: Prevention of Human Immunodeficiency Virus \(HIV\) Infection: Preexposure Prophylaxis](#). June 2019. Accessed September 28, 2020. <https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/prevention-of-human-immunodeficiency-virus-hiv-infection-pre-exposure-prophylaxis>
- 51 [Summary of information on the safety and effectiveness of syringe services programs \(SSPs\)](#). Centers for Disease Control and Prevention. Accessed December 21, 2020. <https://www.cdc.gov/ssp/syringe-services-programs-summary.html>
- 52 Kirzinger A, Lopes L, Wu B, et al., Kaiser Family Foundation. [KFF Health Tracking Poll – March 2019: Public Opinion on the Domestic HIV Epidemic, Affordable Care Act, and Medicare-for-all](#). March 26, 2019. Accessed September 28, 2020. <https://www.kff.org/hivaids/poll-finding/kff-health-tracking-poll-march-2019>
- 53 Wejnert C, Prejean J, Hoots B, et al. [Prevalence of missed opportunities for HIV testing among persons unaware of their infection \[published correction appears in JAMA](#). 2018;320(5):510]. *JAMA*. 2018;319(24):2555-2557. doi:10.1001/jama.2018.7611
- 54 [The state of STDs—infographic](#). Centers for Disease Control and Prevention. Accessed October 16, 2020. <https://www.cdc.gov/std/stats18/infographic.htm>
- 55 Huang YA, Zhu W, Smith DK, et al. [HIV preexposure prophylaxis, by race and ethnicity—United States, 2014–2016](#). *MMWR*. 2018;67:1147-1150. doi:http://dx.doi.org/10.15585/mmwr.mm6741a3.
- 56 Sullivan P, et al. [The impact of pre-exposure prophylaxis with TDF/FTC on HIV diagnoses, 2012-2016, United States](#). 22nd International AIDS Conference (AIDS 2018), Amsterdam, abstract LBPEC036, 2018. Accessed January 10, 2021. https://www.natap.org/2018/IAC/IAC_17.htm

- 57 Canary L, Hariri S, Campbell C, et al. [Geographic disparities in access to syringe services programs among young persons with hepatitis C virus infection in the United States](#). *Clin Infect Dis*. 2017;65(3):514-517. doi:10.1093/cid/cix333
- 58 Sharp A, Jones A, Honermann B, Millett G. [220 Vulnerable Counties: One year later](#). [Poster presentation] Conference on Retroviruses and Opportunistic Infections (CROI). 2018 March. Accessed December 23, 2020. <https://www.croiconference.org/abstract/220-vulnerable-counties-one-year-later/>
- 59 Lazar NR, Salas-Humara C, Wood SM, et al. [Missed opportunities for HIV screening among a cohort of adolescents with recently diagnosed HIV infection in a large pediatric hospital care network](#). *J Adolesc Health*. 2018;63(6):799-802. doi:10.1016/j.jadohealth.2018.07.010
- 60 Traynor SM, Rosen-Metsch L, Feaster DJ. [Missed opportunities for HIV testing among STD clinic patients](#). *J Comm Health*. 2019;43(6):1128-1136. <https://doi.org/10.1007/s10900-018-0531-z>
- 61 Downing A, Garcia-Diaz JB. [Missed opportunities for HIV diagnosis](#). *J Int Assoc Provid AIDS Care*. 2017;16(1):14-17. <https://doi.org/10.1177/2325957416661423>
- 62 DeRose J, Zucker J, Cennimo D, et al. (2017). [Missed testing opportunities for HIV screening and early diagnosis in an urban tertiary care center](#). *AIDS Res Treat*. 2017. <https://doi.org/10.1155/2017/5708620>
- 63 Parish CL, Siegel K, Liguori T, et al. [HIV testing in the dental setting: perspectives and practices of experienced dental professionals](#). *AIDS Care*. 2018;30(3):347-352. doi:10.1080/09540121.2017.1367087
- 64 Centers for Disease Control and Prevention. [HIV Testing Implementation Guidance for Correctional Settings](#); January 2009. Accessed December 23, 2020. <https://stacks.cdc.gov/view/cdc/5279>
- 65 Solomon L, Montague BT, Beckwith CG, et al. [Survey finds that many prisons and jails have room to improve HIV testing and coordination of postrelease treatment](#). *Health Affairs (Project Hope)*. 2014;33(3):434-442. <https://doi.org/10.1377/hlthaff.2013.1115>
- 66 Flanigan TP, Zaller N, Beckwith CG, et al. [Testing for HIV, sexually transmitted infections, and viral hepatitis in jails: Still a missed opportunity for public health and HIV prevention](#). *J Acquir Immune Defic Syndr*. 1999;55 Suppl 2:S78-S83. doi:10.1097/QAI.0b013e3181fbc94f
- 67 [Advancing the ending the HIV Epidemic Initiative with a \\$109 million investment in 57 areas of the United States](#). Centers for Disease Control and Prevention. Accessed September 28, 2020. https://www.cdc.gov/nchhstp/dear_colleague/2020/dcl-073120-ehe-initiative.html
- 68 Weston EJ, Workowski KA, Torrone E, et al. [Adherence to CDC recommendations for the treatment of uncomplicated gonorrhea—STD surveillance network, United States, 2016](#). *Morb Mortal Wkly Rep*. 2018;67(16):473-476. doi:http://dx.doi.org/10.15585/mmwr.mm6716a4
- 69 Seth P, Wang G, Sizemore E, et al. [HIV testing and HIV service delivery to 81 of 87 populations at high risk attending sexually transmitted disease clinics in the United States, 2011-2013](#). *Am J Public Health*. 2015;105(11):2374-81. doi:10.2105/AJPH.2015.302778
- 70 Hoover KW, Parsell BW, Leichter JS, et al. [Continuing need for sexually transmitted disease clinics after the Affordable Care Act](#). *Am J Public Health*. 2015;105 Suppl 5:S690-S695. doi:10.2105/AJPH.2015.302839
- 71 Breuner CC, Mattson G. [Sexuality education for children and adolescents](#). *Pediatrics*. 2016;138(2):e20161348. doi:https://doi.org/10.1542/peds.2016-1348

- 72 [The New York City HIV Status Neutral Prevention and Treatment Cycle](https://www1.nyc.gov/site/doh/health/health-topics/hiv-status-neutral-prevention-and-treatment-cycle.page). City of New York. Accessed December 23, 2020. <https://www1.nyc.gov/site/doh/health/health-topics/hiv-status-neutral-prevention-and-treatment-cycle.page>
- 73 Myers JE, Braunstein SL, et al. [Redefining prevention and care: A status-neutral approach to HIV](#). *Open Forum Infect Dis*. 2018;5(6):ofy097. doi:10.1093/ofid/ofy097
- 74 [Male condom use](#). Effectiveness of Prevention Strategies to Reduce the Risk of Acquiring or Transmitting HIV. Centers for Disease Control and Prevention. Accessed September 28, 2020. https://www.cdc.gov/hiv/risk/estimates/preventionstrategies.html#anchor_1562942368
- 75 [Preventing sexual transmission of HIV](#). HIV.gov. Accessed September 28, 2020. <https://www.hiv.gov/hiv-basics/hiv-prevention/reducing-sexual-risk/preventing-sexual-transmission-of-hiv>
- 76 Satcher, D. [Evidence-based findings on the efficacy of syringe programs: analysis from the Assistant Secretary for Health and Surgeon General of the scientific research completed since April 1998](#). U.S. Department of Health and Human Services; 2000. Accessed December 23, 2020. <http://harmreduction.org/hrc/wp-content/uploads/2012/01/EvidenceBasedFindingsOnEfficacyofSEPs.pdf>
- 77 [MAT medications, counseling, and related conditions](#). Substance Abuse and Mental Health Services Administration. Accessed September 28, 2020. <https://www.samhsa.gov/medication-assisted-treatment/medications-counseling-related-conditions>
- 78 Rothman J, Rudnick D, Slifer M, et al. [Co-located substance use treatment and HIV prevention and primary care services, New York State, 1990-2002: a model for effective service delivery to a high-risk population](#). *J Urban Health*. 2007;84(2):226-242. doi:10.1007/s11524-006-9137-3
- 79 Agency for Health Care Research and Quality. [2009 National Healthcare Quality Report](#); March 2010. Accessed September 28, 2020. <http://archive.ahrq.gov/research/findings/nhqrdr/nhqr09/Key.html>
- 80 Douthit N, Kiv S, Dwolatzky T, et al. [Exposing some important barriers to health care access in the rural USA](#). *Public Health*. 2015;129(6):611-620. doi:10.1016/j.puhe.2015.04.001
- 81 Henny KD, Duke CC, Geter A, et al. [HIV-related training and correlates of knowledge, HIV screening and prescribing of nPEP and PrEP among primary care providers in Southeast United States, 2017](#). *AIDS Behav*. 2019;23(11):2926-2935. doi:10.1007/s10461-019-02545-1
- 82 Pleuhs B, Quinn KG, Walsh JL, et al. [Health care provider barriers to HIV pre-exposure prophylaxis in the United States: a systematic review](#). *AIDS Patient Care STDS*. 2020;34(3):111-123. doi:10.1089/apc.2019.0189
- 83 Farmer EK, Koren DE, Cha A, et al. [The pharmacist's expanding role in HIV pre-exposure prophylaxis](#). *AIDS Patient Care STDS*. 2019;33(5):207-213. doi:10.1089/apc.2018.0294
- 84 Weidle PJ, Lecher S, Botts LW, et al. [HIV testing in community pharmacies and retail clinics: a model to expand access to screening for HIV infection](#). *J Am Pharm Assoc (2003)*. 2014;54(5):486-492. doi:10.1331/JAPhA.2014.14045
- 85 Cantwell-McNelis K, James CW. [Role of clinical pharmacists in outpatient HIV clinics](#). *Am J Health Syst Pharm*. 2002;59(5):447-52. doi:https://doi.org/10.1093/ajhp/59.5.447

- ⁸⁶ U.S. Department of Health and Human Services. [Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents in HIV](https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/10/initiation-of-antiretroviral-therapy). Accessed October 16, 2020. <https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/10/initiation-of-antiretroviral-therapy>
- ⁸⁷ INSIGHT START Study Group, Lundgren JD, Babiker AG, et al. [Initiation of antiretroviral therapy in early asymptomatic HIV infection](https://doi.org/10.1056/NEJMoa1506816). *N Engl J Med*. 2015;373(9):795-807. doi:10.1056/NEJMoa1506816
- ⁸⁸ TEMPRANO ANRS Study Group, Danel C, Moh R, et al. [A trial of early antiretrovirals and isoniazid preventive therapy in Africa](https://doi.org/10.1056/NEJMoa1507198). *N Engl J Med*. 2015;373(9):808-822. doi:10.1056/NEJMoa1507198.
- ⁸⁹ [What is the HIV Care Continuum](https://www.hiv.gov/federal-response/policies-issues/hiv-aids-care-continuum). HIV.gov. Accessed November 12, 2020. <https://www.hiv.gov/federal-response/policies-issues/hiv-aids-care-continuum>
- ⁹⁰ Osborn CY, Paasche-Orlow MK, Davis TC, et al. [Health literacy: an overlooked factor in understanding HIV health disparities](https://doi.org/10.1016/j.amepre.2007.07.022). *Am J Prev Med*. 2007;33(5):374-378. doi:10.1016/j.amepre.2007.07.022
- ⁹¹ Hutchinson P, Dhairyawan R. [Shame and HIV: Strategies for addressing the negative impact shame has on public health and diagnosis and treatment of HIV](https://doi.org/10.1111/bioe.12378). *Bioethics*. 2018;32(1):68-76. doi:10.1111/bioe.12378
- ⁹² Griffin A, Dempsey A, Cousino W, et al. [Addressing disparities in the health of persons with HIV attributable to unstable housing in the United States: The role of the Ryan White HIV/AIDS Program](https://doi.org/10.1371/journal.pmed.1003057). *PLoS Med*. 2020;17(3):e1003057. doi:10.1371/journal.pmed.1003057
- ⁹³ Bacon O, Chin JC, Hsu L, et al. [The Rapid Art Program Initiative For HIV Diagnoses \(RAPID\) in San Francisco](https://www.natap.org/2018/CROI/croi_51.htm). Paper presented at: Conference on Retroviruses and Opportunistic Infections; March 4-7, 2018; Boston, MA. Accessed January 7, 2021. https://www.natap.org/2018/CROI/croi_51.htm
- ⁹⁴ Colasanti J, Sumitani J, Mehta CC, et al. [Implementation of a rapid entry program decreases time to viral suppression among vulnerable persons living with HIV in the Southern United States](https://doi.org/10.1093/ofid/ofy104). *Open Forum Infect Dis*. 2018;5:ofy104. doi:https://doi.org/10.1093/ofid/ofy104
- ⁹⁵ Halperin J, Butler I, Conner K, et al. [Linkage and antiretroviral therapy within 72 hours at a federally qualified health center in New Orleans](https://doi.org/10.1089/apc.2017.0309). *AIDS Patient Care STDS*. 2018;32:39-41. doi:10.1089/apc.2017.0309
- ⁹⁶ Ruria EC, Masaba R, Kose J, et al. [Optimizing linkage to care and initiation and retention on treatment of adolescents with newly diagnosed HIV infection](https://doi.org/10.1097/QAD.0000000000001538). *AIDS*. 2017;31(Suppl 3):S253-S260. doi:10.1097/QAD.0000000000001538
- ⁹⁷ [Red carpet](https://www.whitman-walker.org/care-program/hiv-care). Whitman-Walker Health. Accessed October 27, 2020. <https://www.whitman-walker.org/care-program/hiv-care>
- ⁹⁸ [Compendium of Evidence-Based Interventions and Best Practices for HIV Prevention](https://www.cdc.gov/hiv/research/interventionresearch/compendium/index.html). Centers for Disease Control and Prevention. Accessed September 28, 2020. <https://www.cdc.gov/hiv/research/interventionresearch/compendium/index.html>
- ⁹⁹ Yehia BR, French B, Fleishman JA, et al. [Retention in care is more strongly associated with viral suppression in HIV-infected patients with lower versus higher CD4 counts](https://doi.org/10.1097/QAI.0000000000000023). *J Acquir Immune Defic Syndr*. 2014;65:333-339. doi:10.1097/QAI.0000000000000023
- ¹⁰⁰ El-Sadr WM, Beauchamp G, Hall HI, et al.; HPTN 065 Study. [Brief report: durability of the effect of financial incentives on HIV viral load suppression and continuity in care: HPTN 065 Study](https://doi.org/10.1097/QAI.0000000000001927). *J Acquir Immune Defic Syndr*. 2019;81(3):300-303. doi:10.1097/QAI.0000000000001927

- ¹⁰¹ Dombrowski JC, Galagan SR, Ramchandani M, et al. [HIV care for patients with complex needs: a controlled evaluation of a walk-in, incentivized care model](#). *Open Forum Infect Dis*. 2019;6(7):ofz294. doi:10.1093/ofid/ofz294
- ¹⁰² Saha S, Korthuis PT, Cohn J, et al. [Primary care provider cultural competence and racial disparities in HIV care and outcomes](#). *J Gen Intern Med*. 2013;28(5):622-629. doi:10.1007/s11606-012-2298-8
- ¹⁰³ [TargetHIV.org](#). Accessed September 28, 2020. <https://targethiv.org/>
- ¹⁰⁴ Crepaz N, Hess KL, Purcell DW, et al. [Estimating national rates of HIV infection among MSM, persons who inject drugs, and heterosexuals in the United States](#). *AIDS*. 2019;33(4):701-708 doi:10.1097/QAD.0000000000002111
- ¹⁰⁵ [Ryan White HIV/AIDS Program Client Populations and Outcomes, Transgender Clients Dataset](#). Health Resources and Services Administration. Accessed December 23, 2020. <https://hab.hrsa.gov/sites/default/files/hab/data/datareports/RSR-2018-trans.pptx>
- ¹⁰⁶ Centers for Disease Control and Prevention. [HIV Surveillance Report, vol. 31. Diagnoses of HIV Infection in the United States and Dependent Areas, 2018 \(Updated\)](#); May 2020. Accessed October 16, 2020. <https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-report-2018-updated-vol-31.pdf>
- ¹⁰⁷ Berchick ER, Barnett JC, Upton RD. [Health Insurance Coverage in the United States: 2018](#). Current Population Reports, P60-267(RV). U.S. Government Printing Office; 2019. Accessed January 7, 2021. <https://www.census.gov/content/dam/Census/library/publications/2019/demo/p60-267.pdf>
- ¹⁰⁸ Institute of Medicine. [Care Without Coverage: Too Little, Too Late](#). National Academies Press; 2002. doi:https://doi.org/10.17226/10367
- ¹⁰⁹ [Social determinants of health](#). HealthyPeople.gov. Accessed October 17, 2020. <https://www.healthypeople.gov/2020/topics-objectives/topic/social-determinants-of-health>
- ¹¹⁰ The National Prevention and Health Promotion Strategy. [The National Prevention Strategy: America's Plan for Better Health and Wellness](#); June 2011. Accessed September 28, 2020. <https://www.hhs.gov/sites/default/files/disease-prevention-wellness-report.pdf>
- ¹¹¹ European Observatory on Health Systems and Policies and Ministry of Social Affairs and Health (Finland). [Health in All Policies: Prospects and Potentials](#); 2006. Accessed September 28, 2020. https://www.euro.who.int/__data/assets/pdf_file/0003/109146/E89260.pdf
- ¹¹² Geter A, Herron AR, Sutton MY. [HIV-related stigma by healthcare providers in the United States: a systematic review](#). *AIDS Patient Care and STDs*; 2018, pp. 418-424. <http://doi.org/10.1089/apc.2018.0114>
- ¹¹³ Galárraga O, Rana A, Rahman M, et al. [The effect of unstable housing on HIV treatment biomarkers: an instrumental variables approach](#). *Soc Sci Med*. 2018;214:70-82. doi:10.1016/j.socscimed.2018.07.051
- ¹¹⁴ Stangl AL, Earnshaw VA, Logie CH, et al. [The Health Stigma and Discrimination Framework: a global, crosscutting framework to inform research, intervention development, and policy on health-related stigmas](#). *BMC Med*. 2019;17(1):31. <https://bmcmmedicine.biomedcentral.com/articles/10.1186/s12916-019-1271-3>
- ¹¹⁵ [HIV and STD criminalization laws](#). Centers for Disease Control and Prevention. Accessed September 28, 2020. <https://www.cdc.gov/hiv/policies/law/states/exposure.html>

- ¹¹⁶ De Jesus M, Williams DR. [The Care and Prevention in the United States Demonstration Project: A call for more focus on the social determinants of HIV/AIDS](#). *Public Health Rep.* 2018;133(2_suppl):28S-33S. doi:10.1177/0033354918801353
- ¹¹⁷ [Search: Sustainable East Africa Research in Community Health](#). Accessed September 28, 2020. <https://www.searchendaids.com/>
- ¹¹⁸ [HIV and pregnant women, infants, and children](#). Centers for Disease Control and Prevention. Accessed December 18, 2020. <https://www.cdc.gov/hiv/group/gender/pregnantwomen/index.html>
- ¹¹⁹ McNeil T, Rowe E. [Looking after the survivors: the health of a cohort of long-term human immunodeficiency virus patients 25 years on](#). *Intern Med J.* 2019;49(5):592-597. doi:10.1111/imj.14165
- ¹²⁰ [Integrated HIV Prevention and Care Plan Guidance, including the Statewide Coordinated Statement of Need, CY 2017- 2021](#). Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention and HIV/AIDS Bureau, Health Resources and Services Administration; June 2015. Accessed September 28, 2020. <https://hab.hrsa.gov/sites/default/files/hab/Global/hivpreventionplan062015.pdf>
- ¹²¹ Sweeney P, DiNenno EA, Flores SA, et al. HIV [Data to Care—using public health data to improve hiv care and prevention](#). *J Acquir Immune Defic Syndr.* 2019;82(Suppl 1):S1-S5. doi:10.1097/QAI.0000000000002059
- ¹²² Towe, VL, Stevens C, Fishcer SH. [Sharing and Integrating HIV Client Data Across Provider Organizations to Improve Service Coordination: A Toolkit](#). RAND Corporation, 2019. Accessed September 28, 2020. <https://www.rand.org/pubs/tools/TL344.html>
- ¹²³ National Academies of Sciences, Engineering, and Medicine. [Opportunities to Improve Opioid Use Disorder and Infectious Disease Services: Integrating Responses to a Dual Epidemic](#). National Academies Press, 2020. <https://doi.org/10.17226/25626>
- ¹²⁴ HRSA Ryan White HIV/AIDS Program. [HRSA's Ryan White HIV/AIDS Program Optimizing HIV Care for People Aging with HIV: Incorporating New Elements of Care Reference Guide for Aging with HIV](#). Accessed November 8, 2020. <https://hab.hrsa.gov/sites/default/files/hab/clinical-quality-management/aging-guide-new-elements.pdf>
- ¹²⁵ [HIV and gay and bisexual men](#). Centers for Disease Control and Prevention. Accessed November 9, 2020. <https://www.cdc.gov/hiv/group/msm/index.html>
- ¹²⁶ Centers for Disease Control and Prevention. [CDC-Funded HIV Testing: United States, Puerto Rico, and the U.S. Virgin Islands, 2017](#). Accessed November 4, 2020. <https://www.cdc.gov/hiv/pdf/library/reports/cdc-hiv-funded-hiv-testing-report-2017.pdf>
- ¹²⁷ [Trends in the prevalence of sexual behaviors and HIV testing National YRBS: 1991–2019](#). Centers for Disease Control and Prevention. Accessed November 9, 2020. https://www.cdc.gov/healthyouth/data/yrbs/factsheets/2019_sexual_trend_yrbs.htm
- ¹²⁸ [Selected national HIV prevention and care outcomes](#). Centers for Disease Control and Prevention. Accessed November 9, 2020. <https://www.cdc.gov/hiv/pdf/library/slidesets/cdc-hiv-prevention-and-care-outcomes-2016.pdf>

- ¹²⁹ [Recent HIV clusters and outbreaks across the United States among people who inject drugs and considerations during the COVID-19 pandemic](#). Centers for Disease Control and Prevention. Accessed November 9, 2020. <https://emergency.cdc.gov/han/2020/han00436.asp>
- ¹³⁰ Hoffmann CJ, Thio CL. [Clinical implications of HIV and hepatitis B co-infection in Asia and Africa](#). *Lancet Infect Dis*. 2007;7(6):402-409. [https://doi.org/10.1016/S1473-3099\(07\)70135-4](https://doi.org/10.1016/S1473-3099(07)70135-4)
- ¹³¹ Chen TY, Ding EL, Seage-ii GR, et al. [Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression](#). *Clin Infect Dis*. 2009;49(10):1605-1615. doi:10.1086/644771
- ¹³² Lo Re V, Kallan MJ, Tate JP, et al. [Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: A cohort study](#). *Ann Intern Med*. 2014;160(6):369-379. doi:10.7326/M13-1829.
- ¹³³ [HIV in the United States and dependent areas](#). Centers for Disease Control and Prevention. Accessed November 9, 2020. <https://www.cdc.gov/hiv/statistics/overview/ataglance.html>
- ¹³⁴ [HIV and African American gay and bisexual men](#). Centers for Disease Control and Prevention. Accessed November 9, 2020. <https://www.cdc.gov/hiv/group/msm/bmsm.html>
- ¹³⁵ [Medicaid & HIV. Kaiser Family Foundation; October 1, 2019](#). Accessed January 7, 2021. <https://www.kff.org/hiv/aids/fact-sheet/medicaid-and-hiv/>
- ¹³⁶ Bernstein KT, Marcus JL, Nieri G, et al. [Rectal gonorrhea and chlamydia reinfection is associated with increased risk of HIV seroconversion](#). *J Acquir Immune Defic Syndr*. 2010;53(4):537-543. doi:10.1097/QAI.0b013e3181c3ef29
- ¹³⁷ Flentje A, Heck NC, Brennan JM, et al. [The relationship between minority stress and biological outcomes: A systematic review](#). *J Behav Med*. 2020 Oct;43(5):673-694. doi:10.1007/s10865-019-00120-6.
- ¹³⁸ Psihopaidas D, Cohen SM, West T, et al. [Implementation science and the Health Resources and Services Administration's Ryan White HIV/AIDS Program's work towards ending the HIV epidemic in the United States](#). *PLoS Med*. 2020 Nov 6;17(11):e1003128. doi:10.1371/journal.pmed.1003128.